Gentherm (THRM) 10-K 24 Feb 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Feb. 17, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Trading Symbol	THRM
Entity Registrant Name	GENTHERM INCORPORATED
Entity Central Index Key	0000903129
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Common Stock, Shares Outstanding		33,208,973
Entity Shell Company	false
Entity File Number	0-21810
Entity Tax Identification Number	95-4318554
Entity Address, Address Line One	21680 Haggerty Road
Entity Address, City or Town	Northville
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48167
City Area Code	248
Local Phone Number	504-0500
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	MI
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, no par value
Document Transition Report	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Public Float			$ 2,049,990,444
Document Annual Report	true
Auditor Firm Id	42
Auditor Name	ERNST & YOUNG LLP
Auditor Location	Detroit, Michigan
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the proxy statement for the 2023 annual meeting of shareholders are incorporated by reference into Part III of this Annual Report to the extent described herein.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 153,891	$ 190,606
Accounts receivable, net	247,131	182,987
Inventory, net	218,248	159,477
Other current assets	64,597	32,775
Total current assets	683,867	565,845
Property and equipment, net	244,480	155,270
Goodwill	119,774	66,033
Other intangible assets, net	73,933	37,554
Operating lease right-of-use assets	29,945	24,387
Deferred income tax assets	69,840	69,630
Other non-current assets	17,461	16,624
Total assets	1,239,300	935,343
Current Liabilities:
Accounts payable	182,225	122,727
Current lease liabilities	7,143	5,669
Current maturities of long-term debt	2,443	2,500
Other current liabilities	93,814	82,193
Total current liabilities	285,625	213,089
Long-term debt, less current maturities	232,653	36,250
Non-current lease liabilities	20,538	19,789
Pension benefit obligation	3,638	6,832
Other non-current liabilities	24,573	5,577
Total liabilities	567,027	281,537
Common Stock:
No par value; 55,000,000 shares authorized 33,202,082 and 33,008,185 issued and outstanding at December 31, 2022 and December 31, 2021, respectively	122,658	118,646
Paid-in capital	5,447	5,866
Accumulated other comprehensive loss	(46,489)	(36,922)
Accumulated earnings	590,657	566,216
Total shareholders’ equity	672,273	653,806
Total liabilities and shareholders’ equity	$ 1,239,300	$ 935,343

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common Stock, par value
Common Stock, shares authorized	55,000,000	55,000,000
Common Stock, shares issued	33,202,082	33,008,185
Common Stock, shares outstanding	33,202,082	33,008,185

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Product revenues	$ 1,204,656	$ 1,046,150	$ 913,098
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of sales	$ 931,006	$ 742,519	$ 644,994
Gross margin	273,650	303,631	268,104
Operating expenses:
Net research and development expenses	85,722	75,214	68,040
Selling, general and administrative expenses	132,693	109,554	105,044
Impairment of intangible assets and property and equipment	6,291
Restructuring expenses	637	3,857	5,803
Total operating expenses	225,343	188,625	178,887
Operating income	48,307	115,006	89,217
Interest expense, net	(4,294)	(2,758)	(4,559)
Foreign currency (loss) gain	(6,778)	1,487	(5,439)
Other income	1,147	117	2,337
Earnings before income tax	38,382	113,852	81,556
Income tax expense	13,941	20,418	21,866
Net income	$ 24,441	$ 93,434	$ 59,690
Basic earnings per share	$ 0.74	$ 2.82	$ 1.83
Diluted earnings per share	$ 0.73	$ 2.79	$ 1.81
Weighted average number of shares – basic	33,126,202	33,085,732	32,666,025
Weighted average number of shares – diluted	33,503,154	33,509,720	33,028,104

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 24,441	$ 93,434	$ 59,690
Other comprehensive (loss) income:
Pension benefit obligations	1,826	558	(80)
Foreign currency translation adjustments	(14,081)	(21,551)	27,242
Unrealized (loss) gain on foreign currency derivative securities, net of tax	2,693	(952)	211
Unrealized (loss) gain on commodity derivative securities, net of tax	(5)	5
Other comprehensive (loss) income, net of tax	(9,567)	(21,940)	27,373
Comprehensive income	$ 14,874	$ 71,494	$ 87,063

Consolidated Statements of Chan

Consolidated Statements of Changes In Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Earnings
Beginning Balance at Dec. 31, 2019	$ 484,096	$ 102,507	$ 10,852	$ (42,355)	$ 413,092
Beginning Balance (in shares) at Dec. 31, 2019		32,674,000
Net income	59,690				59,690
Other comprehensive income (loss)	27,373			27,373
Stock compensation, net	24,264	$ 27,658	(3,394)
Stock compensation, net, shares		493,000
Stock repurchase	(9,092)	$ (9,092)
Stock repurchase (in shares)		(246,000)
Ending Balance at Dec. 31, 2020	586,331	$ 121,073	7,458	(14,982)	472,782
Ending Balance (in shares) at Dec. 31, 2020		32,921,000
Net income	93,434				93,434
Other comprehensive income (loss)	(21,940)			(21,940)
Stock compensation, net	15,981	$ 17,573	(1,592)
Stock compensation, net, shares		327,000
Stock repurchase	(20,000)	$ (20,000)
Stock repurchase (in shares)		(240,000)
Ending Balance at Dec. 31, 2021	$ 653,806	$ 118,646	5,866	(36,922)	566,216
Ending Balance (in shares) at Dec. 31, 2021	33,008,185	33,008,000
Net income	$ 24,441				24,441
Other comprehensive income (loss)	(9,567)			(9,567)
Stock compensation, net	3,593	$ 4,012	(419)
Stock compensation, net, shares		194,000
Ending Balance at Dec. 31, 2022	$ 672,273	$ 122,658	$ 5,447	$ (46,489)	$ 590,657
Ending Balance (in shares) at Dec. 31, 2022	33,202,082	33,202,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating Activities:
Net income	$ 24,441	$ 93,434	$ 59,690
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	44,394	38,780	41,114
Deferred income taxes	(7,322)	(150)	849
Stock based compensation	6,599	14,530	8,829
Loss on disposition of property and equipment	771	973	683
Impairment of intangible assets and property and equipment	6,291
Provisions for inventory	15,923	2,499	1,768
Gain on sale of patents			(1,978)
Other	721	(271)	(748)
Changes in assets and liabilities:
Accounts receivable, net	(44,221)	25,099	(46,742)
Inventory	(40,322)	(42,372)	(2,582)
Other assets	(11,906)	10,307	(11,997)
Accounts payable	28,314	8,166	29,960
Other liabilities	(8,736)	(7,919)	31,849
Net cash provided by operating activities	14,947	143,076	110,695
Investing Activities:
Purchases of property and equipment	(39,703)	(38,468)	(17,219)
Proceeds from the sale of patents and property and equipment	248	22	2,140
Acquisition of businesses, net of cash acquired	(205,487)	(2,827)
Proceeds from deferred purchase price of factored receivables	5,538
Cost of technology investments	(495)	(7,557)
Acquisition of intangible assets			(3,141)
Net cash used in investing activities	(239,899)	(48,830)	(18,220)
Financing Activities:
Borrowings on debt	207,000		201,194
Repayments of debt	(13,272)	(153,243)	(91,439)
Proceeds from the exercise of Common Stock options	1,670	8,279	16,552
Taxes withheld and paid on employees' share-based payment awards	(5,471)	(4,108)	(1,117)
Cash paid for the repurchase of Common Stock		(20,000)	(9,092)
Acquisition contingent consideration payment		(69)	(618)
Net cash provided by (used in) provided by financing activities	189,927	(169,141)	115,480
Foreign currency effect	(1,690)	(2,844)	7,442
Net (decrease) increase in cash and cash equivalents	(36,715)	(77,739)	215,397
Cash and cash equivalents at beginning of period	190,606	268,345	52,948
Cash and cash equivalents at end of period	153,891	190,606	268,345
Supplemental disclosure of cash flow information:
Cash paid for taxes	21,645	14,857	5,013
Cash paid for interest	$ 6,338	$ 2,378	$ 4,204

Overview

Overview	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Overview	Note 1 — Overview Gentherm Incorporated, a Michigan corporation, and its consolidated subsidiaries (“Gentherm”, “we”, “us”, “our” or the “Company”) is a global developer, manufacturer and marketer of innovative thermal management and pneumatic comfort technologies for a broad range of heating, cooling and temperature control applications, as well as lumbar and massage comfort solutions, primarily in the automotive and medical industries. Within the automotive industry, our products provide solutions for passenger comfort and convenience, battery thermal management and cell connecting systems. Within the medical industry our products provide patient temperature management solutions. Our automotive products can be found on vehicles manufactured by nearly all the major automotive original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. The Company also is developing a number of new technologies and products that are expected to enable improvements to existing products and will lead to new product applications for existing and new markets. On July 13, 2022, Gentherm acquired Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”), a manufacturer of medical materials and medical equipment, including patient temperature management solutions. The acquisition was accounted for as a business combination within our Medical segment. On August 1, 2022, Gentherm acquired Alfmeier Präzision SE (“Alfmeier”), a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems technology, integrated electronics and software. The acquisition was accounted for as a business combination within our Automotive segment. See Note 4, "Acquisitions," to the consolidated financial statements included in this Annual Report for additional information.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20 %), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Intercompany transactions and balances between consolidated businesses have been eliminated. Use of Estimates In preparing these consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. Business combinations In accordance with ASC Topic 805, “Business Combinations,” acquisitions are recorded using the acquisition method of accounting. The Company includes the operating results of acquired entities from their respective dates of acquisition. The Company recognizes and measures the identifiable assets acquired, liabilities assumed, and any non-controlling interest as of the acquisition date fair value. The excess, if any, of total consideration transferred in a business combination over the fair value of identifiable assets acquired, liabilities assumed and any non-controlling interest is recognized as goodwill. Costs incurred as a result of a business combination other than costs related to the issuance of debt or equity securities are recorded in the period the costs are incurred. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to assets acquired and liabilities assumed with the corresponding offset to goodwill. Segment Reporting The Company has two reportable segments: Automotive and Medical . The Automotive reporting segment is comprised of the results from our global automotive businesses, including the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, lumbar and massage comfort solutions, valve system technologies, battery performance solutions, and automotive electronic and software systems. The Medical reporting segment is comprised of the results from the patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute care, ambulatory, clinics and home health. Revenue Recognition Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from Product revenues. Shipping and handling fees billed to customers are included in Product revenues, while costs of shipping and handling are included in Cost of sales. Automotive Revenues The Company provides production parts to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, a LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from its customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts. Certain LTAs provide for annual price reductions over the production life of the vehicle. Agreements that are determined to provide customers with purchase option discounts that would not be received without entering into the contract are considered to contain a material right (for example, a discount given to a customer that is incremental to the range of discounts typically given to that class of customer). The material right represents a purchase option that provides the customer with the ability to purchase additional production parts at a set price in the future and is accounted for as a separate performance obligation. Under these circumstances, each transfer of production parts under the LTA requires allocation of the purchase price to the production part and the purchase option. As a practical alternative to estimating the standalone selling price of an option, the Company allocates transaction price to the purchase option by reference to the production part volumes expected to be ordered and the consideration expected to be received over the life of the vehicle program. The production part’s relative standalone selling price observed under the LTA is subtracted from the total amount of consideration expected to be received in exchange for transferring of parts under the current contract and the difference is allocated to the purchase option. Revenue from options containing a material right is recognized when the amounts billed to the customer for production parts transferred, under the LTA, is less than the standalone selling price of those production parts. Medical Revenues Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on body and blood temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized at the point in time the medical products or equipment is transferred to the customer. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company has no material contract assets or contract liabilities as of December 31, 2022. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year . Total capitalized costs to obtain a contract were $ 2,239 and $ 1,946 as of December 31, 2022 and 2021, respectively. These amounts are recorded in Other non-current assets and are being amortized into Product revenues over the expected production life of the applicable program. During the year ended December 31, 2022 and 2021 , $ 78 and $ 174 , respectively, was amortized into Product revenues. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. Cash balances in individual banks may exceed the federally insured limit by the Federal Deposit Insurance Corporation. The Company had Cash and cash equivalents of $ 108,620 and $ 161,496 held in foreign jurisdictions as of December 31, 2022 and 2021 , respectively. Disclosures About Fair Value of Financial Instruments The carrying amounts of financial instruments comprising cash and cash equivalents, short-term investments, accounts receivable, notes receivable and accounts payable approximate fair value because of the short maturities of these instruments. The carrying amount of the Company’s revolving credit note under the June 10, 2022 amended and restated credit agreement (“Credit Agreement”) approximates its fair value because interest charged on the loan balance is variable. See Note 14, “Fair Value Measurement,” for information about the techniques used to assess the fair value of financial assets and liabilities, including our fixed rate debt instruments. Concentration of Credit Risk Financial assets, which subject the Company to concentration of credit risk, consist primarily of cash equivalents, short-term investments, accounts receivable and notes receivable. Cash equivalents consist primarily of money market funds managed by major financial services companies. The credit risk for these cash equivalents is considered low. The Company does not require collateral from its customers. As of December 31, 2022 , the Company’s Automotive customers, Adient and Lear both individually represented 18 % and 17 %, respectively, of the Company’s accounts receivable balance. As of December 31, 2021 , the Company’s Automotive customers, Adient and Lear both individually represented 22 % and 18 %, respectively, of the Company’s accounts receivable balance. Accounts Receivable Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company determines the allowances based on historical write-off experience by industry and regional economic data, current expectations of future credit losses and historical cash discounts. The Company’s accounts receivables are continually assessed for collectability and any allowance is recorded based upon the age of outstanding receivables, historical payment experience and customer creditworthiness. We write-off accounts receivable when they become uncollectible. The allowance for doubtful accounts was $ 1,220 and $ 1,399 as of December 31, 2022 and 2021, respectively. The reconciliation of the beginning and ending amount of the allowance for doubtful accounts is as follows: Year Ended December 31, 2022 2021 2020 Balance at beginning of year $ 1,399 $ 1,161 $ 1,193 Charged to costs and expenses 1,088 1,066 1,298 Other activity - ( 12 ) 33 Deductions from reserves ( 1,267 ) ( 816 ) ( 1,363 ) Balance at end of year $ 1,220 $ 1,399 $ 1,161 Primarily in the Asia-Pacific region, the Company receives bank notes from certain customers to settle trade receivables. The collection of such bank notes is included in operating cash flows based on the substance of the underlying transactions, which are operating in nature. Bank notes held by the Company are classified as notes receivable within other current assets. The Company may hold such bank notes until maturity, exchange them with suppliers to settle liabilities, or sell them to third-party financial institutions in exchange for cash. Inventory The Company’s inventory is measured at the lower of cost or net realizable value. Raw materials, components and consumables are measured using the weighted average cost method. Work-in-process and finished goods are measured using the first-in first-out method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months' supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve. Property and Equipment Property and equipment, including additions and improvements, are recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as Operating income or expense. The Company evaluates the recoverability of long-lived assets when events and circumstances indicate that the assets may be impaired and the undiscounted net cash flows estimated to be generated by those assets are less than their carrying value. If the net carrying value exceeds the fair value, an impairment loss exists and is calculated based on either estimated salvage value or estimated orderly liquidation value. Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years The Company recognized depreciation expense of $ 33,730 , $ 29,622 and $ 31,037 for the years ended December 31, 2022, 2021 and 2020 , respectively. Tooling The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in Other current assets in the accompanying consolidated balance sheets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2022 and 2021 , the Company had $ 15,267 and $ 3,778 , respectively, of reimbursable tooling costs capitalized. Company-owned tooling is included in Property and equipment and depreciated over its expected useful life, generally two to ten years . Goodwill and Other Intangible Assets Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition. Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 12 years Product development costs 5 to 10 years Trade names Indefinite Software development costs 4 to 5 years Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. All costs associated with the development and issuance of new patents are expensed as incurred. Such costs are classified as research and development expenses in the accompanying consolidated statements of income. Impairments of Other Intangible Assets and Goodwill Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized. The Company utilizes an income approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in our industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect a risk factor, if necessary. Other significant assumptions include terminal value growth rates and terminal value margin rates. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income approach provides a reasonable estimate of the fair value of a reporting unit. The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Investments in non-consolidated affiliates During 2021, the Company’s Automotive segment invested $ 5,200 for an ownership interest in Carrar Ltd. (“Carrar”), an Israel-based technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. During 2021, the Company’s Automotive segment invested $ 2,357 for an ownership interest in Forciot Oy (“Forciot”), a Finland-based technology developer of sensors for touch, motion and force measurement. Gentherm’s investment in Forciot is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. In December 2021, the Company committed to make a $ 5,000 investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten-year life of the fund. The Company has made contributions totaling approximately $ 495 to the Autotech Fund III, LP as of December 31, 2022. This fund focuses broadly on the automotive industry and compliments the Company’s innovation strategy. Research and Development Expenses Research and development activities are expensed as incurred. The Company groups development and prototype costs and related reimbursements in research and development. Leases The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles. Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 9 years and may include options to extend the lease. Land leases have remaining lease terms that range from 3 to 40 years and some which specify that the end of the lease term is at the discretion of the lessee. We do not have lease arrangements with related parties. The Company determines whether a contractual arrangement is or contains a lease at inception. Leases that are operating in nature are recognized in Operating lease right-of-use assets, Current lease liabilities and Non-current lease liabilities in the accompanying consolidated balance sheets. Finance leases are included in property and equipment, net, current maturities of long-term debt, and long-term debt on the Company’s consolidated balance sheets. Lease liabilities are measured initially at the present value of the sum of the future minimum rental payments at the commencement date of the lease. Lease payments that will vary in the future due to changes in facts and circumstances are excluded from the calculation of rental payments, unless those variable payments are based on an index or rate. Rental payments are discounted using an incremental borrowing rate, unless there is a rate implicit in the lease agreement. The incremental borrowing rate is based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). Judgment is used to assess the importance of risk factor inputs during the computation of the Company’s credit rating. For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate. Operating lease right-of-use assets are measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentive received, and initial direct costs incurred, as applicable. Periods covered by an option to extend the lease are initially included in the measurement of an operating lease right-of-use asset and lease liability only when it is reasonably certain we will exercise the option. Gentherm’s lease agreements do not contain residual value guarantees or impose restrictions or covenants on the Company. For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income. Income Taxes The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2022 and 2021, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized. If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in Income tax expense. Derivative Financial Instruments – Hedge Accounting All derivative instruments are required to be reported on the balance sheet at fair value unless the transactions qualify and are designated as normal purchases or sales. Changes in fair value are reported currently through earnings unless they meet hedge accounting criteria. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. The Company accounts for its designated derivative financial instruments as cash flow hedges. For derivative contracts which are designated as a cash flow hedge, the effective portion of the change in the fair value of the derivative contract is recorded to Accumulated other comprehensive loss (“AOCI”) in the accompanying consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in AOCI is recorded into earnings in the accompanying consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. Any ineffective portion of the gain or loss is recognized in the accompanying consolidated statements of income under Foreign currency gain (loss) for foreign currency derivatives, and cost of goods sold for commodity derivatives. These hedging transactions and the respective correlations meet the requirements for hedge accounting. Exposure to fluctuations in interest rates and certain commodity prices are managed by entering into swaps with various counterparties. The Company does not enter into derivative transactions for speculative or trading purposes. As part of the hedging program approval process, Gentherm identifies the specific financial risk which the derivative transaction will minimize, the appropriate hedging instrument to be used to reduce the risk and the correlation between the financial risk and the hedging instrument. Hedge positions, as well as the correlation between the transaction risks and the hedging instruments, are reviewed on an ongoing basis. Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the respective period. The Company’s diluted earnings per share give effect to all potential shares of common stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of common stock equivalents. Stock Based Compensation Share based payments that involve the issuance of common stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the consolidated financial statements as compensation expense based upon the fair value on the date of grant. Share based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense.

New Accounting Pronouncements

New Accounting Pronouncements	12 Months Ended
	Dec. 31, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Pronouncements	Note 3 — New Accounting Pronouncements Recently Adopted Accounting Pronouncements Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting”. ASU 2020-04 provides practical expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments in this update apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate or another reference rate expected to be discontinued as a result of reference rate reform. These amendments are not applicable to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. In January 2021, the FASB subsequently issued ASU 2021-01, “Reference Rate Reform (Topic 848): Scope” to clarify that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. ASU 2020-04 and ASU 2021-01 are effective as of March 12, 2020 through December 31, 2022 and may be applied retrospectively to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020, or on a prospective basis to new modifications from any date within an interim period that includes or is subsequent to the date of the issuance of a final update, up to the date that financial statements are available to be issued. Upon adoption of this standard, the Company does not expect it to have a material impact to the Company’s financial statements.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Acquisitions	Note 4 – Acquisitions Alfmeier Präzision SE On August 1, 2022 , the Company acquired 100 % of the equity interests of Alfmeier, a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems technology, integrated electronics and software. The acquisition further expands the Company's current value proposition beyond thermal to comfort, health, wellness, and energy efficiency and aligns with global consumer demand for expanded offerings in vehicle passenger comfort. The total consideration transferred was $ 170,700 , including cash consideration of $ 170,439 and amounts due to seller of $ 261 . The results of Alfmeier's operations are reported within the Automotive segment from the acquisition date. The following table provides product revenues and operating income from Alfmeier that are included in our consolidated financial statements: Year Ended December 31, 2022 Product revenues $ 98,960 Net loss ( 2,675 ) Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable. The following table summarizes the purchase consideration to the fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments: Initial Allocation Measurement Period Adjustments Revised Allocation Purchase price, consideration, net of cash acquired (a) $ 164,887 $ 5,813 $ 170,700 — Accounts receivable 24,988 ( 121 ) 24,867 Inventory 36,026 ( 106 ) 35,920 Prepaid expenses and other assets 20,920 ( 74 ) 20,846 Operating lease right-of-use assets 4,608 — 4,608 Property and equipment 89,942 1,242 91,184 Other intangible assets 22,668 8,791 31,459 Goodwill 43,678 ( 9,184 ) 34,494 Assumed liabilities ( 55,994 ) 975 ( 55,019 ) Deferred tax liabilities ( 21,949 ) 4,290 ( 17,659 ) Net assets acquired $ 164,887 $ 5,813 $ 170,700 (a) Purchase price includes cash paid of $ 170,439 plus amounts due to seller of $ 261 . The following table summarizes the allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 19,812 14 Technology 11,647 9 Total $ 31,459 The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from combining operations to offer more compelling and high-value solutions across complementary customer relationships as well as expected future synergies. The goodwill is not expected to be deductible for tax purposes. The following unaudited pro forma information represents our product revenues and net income as if the acquisition of Alfmeier had occurred as of January 1, 2021: Year Ended December 31, 2022 2021 Product revenues $ 1,348,295 $ 1,304,505 Net Income 17,645 92,079 Jiangmen Dacheng Medical Equipment Co. Ltd On July 13, 2022 , the Company acquired 100 % of the equity interests of Dacheng and its wholly owned subsidiary, IOB Medical, Inc. Dacheng, is a manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provides Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, while also expanding overall manufacturing capacity to include a low-cost manufacturing site. The total consideration was $ 35,048 , which is comprised of cash payments, net of cash acquired. The purchase agreement also includes future cash payments of up to $ 3,000 , contingent upon the achievement of certain performance metrics and continued employment of the former majority shareholder through a series of defined dates. These contingent payments will be accounted for as compensation expense and will be recorded as a component of selling, general and administrative. The results of Dacheng's operations are reported within the Medical segment from the date of acquisition. The following table provides product revenues and operating income from Dacheng that are included in our consolidated financial statements: Year Ended December 31, 2022 Product revenues $ 3,499 Net Loss ( 217 ) Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable. The following table summarizes the purchase consideration to the fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments: Initial Allocation Measurement Period Adjustments Revised Allocation Purchase price, cash consideration, net of cash acquired $ 35,048 $ — $ 35,048 — Accounts receivable 746 ( 84 ) 662 Inventory 1,942 ( 177 ) 1,765 Prepaid expenses and other assets 152 22 174 Operating lease right-of-use assets 841 — 841 Property and equipment 684 — 684 Other intangible assets 19,094 965 20,059 Goodwill 22,995 ( 3,979 ) 19,016 Assumed liabilities ( 2,799 ) ( 40 ) ( 2,839 ) Deferred tax liabilities ( 8,607 ) 3,293 ( 5,314 ) Net assets acquired $ 35,048 $ — $ 35,048 The following table summarizes the allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 12,837 12 Technology 4,749 12 Indefinite-lived: Tradenames 2,473 — Total $ 20,059 The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from the enhanced access to high-growth markets including private label opportunities through Dacheng’s innovative patient temperature management devices. The goodwill is not expected to be deductible for tax purposes. The pro forma effects of this acquisition would not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented. Acquisition of Beckmann & Egle Industrieelektronik GmbH On July 1, 2021, the Company acquired the medical business unit of Beckmann & Egle Industrieelektronik GmbH (“B&E”), a developer and manufacturer of electronic control units, for a purchase price of $ 2,827 . The acquisition was accounted for as a business combination with the purchase price assigned to inventory, property and equipment and other intangible assets based on their estimated fair values as of the acquisition date. The results of operations of B&E are reported within the Company’s Medical segment from the date of acquisition.

Restructuring and Impairments

Restructuring and Impairments	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring and Impairments	Note 5 — Restructuring and Impairments The Company continuously monitors market developments, industry trends and changing customer needs and in response, may undertake restructuring actions, as necessary, to execute management’s strategy, streamline operations and optimize the Company’s cost structure. Restructuring actions may include the realignment of existing manufacturing footprint, facility closures, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in employees receiving voluntary or involuntary employee termination benefits, which are mainly statutory requirements or other contractual agreements. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and when the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. Manufacturing Footprint Rationalization During 2019, the Company committed to a restructuring plan (“Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this Plan, the Company relocated and consolidated certain automotive electronics manufacturing plants in North America and China. During the year ended December 31, 2022 , the Company recognized restructuring expense of $ 56 for employee separation costs and $ 198 for other costs, primarily related to equipment move and set up costs. During the year ended December 31, 2021 , the Company recognized restructuring expense of $ 1,303 for employee separation costs and $ 1,665 for other costs, primarily related to equipment move and set up costs. During the year ended December 31, 2020 , the Company recognized restructuring expense of $( 832 ) for employee separation costs and $ 1,019 for other costs, primarily related to accelerated depreciation and equipment move and set up costs. The net activity for the year ended December 31, 2020 was primarily related to a reduction in the estimates of previously recognized employee separation costs. The Company has recorded approximately $ 10,359 of restructuring expenses since the inception of this program and as of December 31, 2022 , $ 588 remains accrued. Other Restructuring Activities The Company has undertaken several discrete restructuring actions. During the years ended December 31, 2022, 2021 and 2020 , the Company recognized $ 0 , $ 889 and $ 5,382 of employee separation costs, respectively, and $ 383 , $ 0 and $ 234 of other related costs, respectively. These restructuring expenses were primarily associated with restructuring actions focused on the rotation of our manufacturing footprint to best cost locations and the reduction of global overhead costs. Restructuring Expenses By Reporting Segment Restructuring expense by reporting segment for the years ended December 31, 2022, 2021 and 2020 was as follows: Year Ended December 31, 2022 2021 2020 Automotive $ 637 $ 2,793 $ 5,075 Medical — — 112 Corporate — 1,064 616 Total $ 637 $ 3,857 $ 5,803 Restructuring Liability The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2022 and 2021: Employee Separation Costs Other Related Costs Total Balance at December 31, 2020 $ 5,627 $ — $ 5,627 Additions, charged to restructuring expenses 2,406 1,927 4,333 Change in estimate ( 214 ) ( 262 ) ( 476 ) Cash payments ( 6,129 ) ( 1,709 ) ( 7,838 ) Non-cash utilization — ( 218 ) ( 218 ) Currency translation and other ( 196 ) 262 66 Balance at December 31, 2021 $ 1,494 $ — $ 1,494 Additions, charged to restructuring expenses 6 581 587 Change in estimate 50 — 50 Cash payments ( 881 ) ( 581 ) ( 1,462 ) Currency translation and other ( 81 ) — ( 81 ) Balance at December 31, 2022 $ 588 $ — $ 588 Impairments – Non-Automotive Electronics Business On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. The Company will continue to sell certain non-automotive electronics products until the exit is complete. The Company is evaluating a potential sale of the non-automotive electronics business or substantially all of its assets. If such sale is not pursued or is unsuccessful, the Company intends to wind-down the operations of the business over approximately eight to twelve months, subject to discussions with customers and suppliers. In the event of a wind-down, certain property, plant and equipment will be utilized by other operations of the Company. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $ 9,378 , $ 5,601 and $ 690 for write downs of inventory, intangible assets and property and equipment, respectively, within the Automotive segment. Write downs of inventory are recorded in Cost of sales. Write downs of intangible assets and property and equipment are recorded in Impairment of intangible assets and property and equipment.

Details of Certain Financial St

Details of Certain Financial Statement Components	12 Months Ended
	Dec. 31, 2022
Financial Statement Components [Abstract]
Details of Certain Financial Statement Components	Note 6 — Details of Certain Financial Statement Components December 31, 2022 2021 Inventory: Raw materials, net of reserve $ 136,217 $ 96,426 Work in process, net of reserve 17,695 9,495 Finished goods, net of reserve 64,336 53,556 Total inventory, net $ 218,248 $ 159,477 Other current assets: Notes receivable $ 12,127 $ 13,033 Income tax and other tax receivable 15,041 10,681 Billable tooling 15,267 3,778 Short-term derivative financial instruments 6,564 300 Prepaid expenses 6,239 3,407 Receivables due from factor 5,490 — Other 3,869 1,576 Total other current assets $ 64,597 $ 32,775 Property and equipment: Machinery and equipment $ 214,342 $ 155,463 Buildings and improvements 123,714 100,788 Information technology 39,726 33,060 Production tooling 24,839 25,180 Leasehold improvements 12,271 11,445 Construction in progress 29,023 14,506 Total property and equipment 443,915 340,442 Less: accumulated depreciation ( 199,435 ) ( 185,172 ) Total property and equipment, net $ 244,480 $ 155,270 Other current liabilities: Accrued employee liabilities $ 32,031 $ 28,818 Liabilities from discounts and rebates 26,640 27,343 Income tax and other taxes payable 14,459 17,068 Restructuring 588 1,494 Accrued warranty 2,380 1,916 Other 17,716 5,554 Total other current liabilities $ 93,814 $ 82,193

Goodwill and Other Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	Note 7 — Goodwill and Other Intangibles Goodwill Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2022 and 2021 were as follows: Automotive Medical Total Balance as of December 31, 2020 $ 39,495 $ 28,529 $ 68,024 Acquisition of B&E — 976 976 Exchange rate impact ( 2,166 ) ( 801 ) ( 2,967 ) Balance as of December 31, 2021 $ 37,329 $ 28,704 $ 66,033 Acquisition of Dacheng — 19,016 19,016 Acquisition of Alfmeier 34,494 — 34,494 Exchange rate impact 1,246 ( 1,015 ) 231 Balance as of December 31, 2022 $ 73,069 $ 46,705 $ 119,774 Other Intangible Assets Other intangible assets and accumulated amortization balances as of December 31, 2022 and 2021 were as follows: Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 112,286 $ ( 65,748 ) $ 46,538 Technology 44,745 ( 25,709 ) 19,036 Product development costs 18,774 ( 18,456 ) 318 Software development 1,007 — 1,007 Indefinite-lived: Tradenames 7,034 — 7,034 Balance as of December 31, 2022 $ 183,846 $ ( 109,913 ) $ 73,933 Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 90,448 $ ( 64,105 ) $ 26,343 Technology 29,464 ( 24,487 ) 4,977 Product development costs 20,329 ( 19,772 ) 557 Software development 1,007 — 1,007 Indefinite-lived: Tradenames 4,670 — 4,670 Balance as of December 31, 2021 $ 145,918 $ ( 108,364 ) $ 37,554 On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business, resulting in an impairment of our customer relationships intangible assets of $ 5,601 . See Note 5, " Restructuring and Impairments ," to the consolidated financial statements included in this Annual Report for additional information. In connection with the acquisition of Alfmeier, the Company recorded technology of $ 11,647 and customer relationships of $ 19,812 . These definite-lived assets are being amortized using the straight-line method over their estimated useful lives of approximately 9 years and 14 years , respectively. In connection with the acquisition of Dacheng, the Company recorded technology of $ 4,749 , customer relationships of $ 12,837 , and indefinite-lived tradenames of $ 2,473 . Technology and customer relationships are definite-lived assets that are being amortized using the straight-line method over their estimated useful lives of approximately 12 years for each. In connection with the acquisition of B&E, the Company recorded technology of $ 976 . These definite-lived assets are being amortized using the straight-line method over their estimated useful lives of approximately seven years . On February 28, 2020, Gentherm acquired the automotive patents and technology of a development-stage technology company for $ 3,141 . The investment was accounted for as an asset acquisition of defensive intangible assets and will be amortized over six years . On June 19, 2020, Gentherm sold patents from a non-core business for $ 2,055 . The gain on sale of $ 1,978 was recorded in Other income in the consolidated statements of income. A total of $ 9,018 , $ 8,821 and $ 9,226 in other intangible assets were amortized in 2022, 2021 and 2020, respectively. An estimate of other intangible asset amortization by year, is as follows: 2023 $ 8,294 2024 $ 7,297 2025 $ 7,284 2026 $ 7,284 2027 $ 7,284

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	Note 8 — Leases Components of lease expense for the years ended December 31, 2022, 2021 and 2020 were as follows: Year Ended December 31, 2022 2021 2020 Lease cost: Operating lease cost $ 8,040 $ 8,227 $ 6,773 Amortization of ROU assets - finance leases 168 — — Interest on lease liabilities - finance leases 16 — — Short-term lease cost 1,773 1,941 1,834 Sublease income ( 101 ) ( 163 ) ( 158 ) Total lease cost $ 9,896 $ 10,005 $ 8,449 Other information related to leases is as follows: Year Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 10,381 $ 7,685 Operating cash flows for finance leases 16 — Financing cash flows for finance leases 164 — Right-of-use lease assets obtained in exchange for lease obligations: Operating leases $ 15,902 $ 2,379 Finance leases 1,180 — December 31, 2022 December 31, 2021 Weighted average remaining lease term: Operating leases 5.7 years 6.9 years Finance leases 2.7 years N/A Weighted average discount rate: Operating leases 4.35 % 4.53 % Finance leases 3.57 % N/A A summary of operating leases as of December 31, 2022, under all non-cancellable operating leases with terms exceeding one year is as follows: 2023 $ 8,074 2024 7,003 2025 4,984 2026 3,122 2027 1,631 2028 or later 6,538 Total future minimum lease payments 31,352 Less imputed interest ( 3,671 ) Total $ 27,681 A summary of finance leases as of December 31, 2022, under all non-cancellable finance leases with terms exceeding one year is as follows: 2023 $ 432 2024 437 2025 148 2026 68 Total future minimum lease payments $ 1,085

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	Note 9 — Debt The following table summarizes the Company’s debt as of December 31, 2022 and 2021: December 31, 2022 2021 Interest Principal Interest Principal Credit Agreement: U.S. Revolving Note (U.S. Dollar denominations) 5.80 % $ 232,000 1.35 % $ 35,000 Other loans 3.89 % - 5.21 % 2,011 5.21 % 3,750 Finance leases N/A 1,085 N/A — Total debt 235,096 38,750 Current maturities ( 2,443 ) ( 2,500 ) Long-term debt, less current maturities $ 232,653 $ 36,250 Credit Agreement On June 10, 2022, the Company entered into a Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent (the “Agent”). The Second Amended and Restated Credit Agreement amended and restated in its entirety the Amended and Restated Credit Agreement dated June 27, 2019, by and among Gentherm, certain of its direct and indirect subsidiaries, the lenders party thereto and the Agent. The Second Amended and Restated Credit Agreement provides for a $ 500,000 secured revolving credit facility (the “Revolving Credit Facility”) (a $ 25,000 increase from the revolving credit facility under the Amended and Restated Credit Agreement), with a $ 50,000 sublimit for swing line loans and a $ 15,000 sublimit for the issuance of standby letters of credit. Any amount of the facility utilized for swing line loans or letters of credit outstanding will reduce the amount available under the Second Amended and Restated Credit Agreement. The Company h ad no out standing letters of credit issued as of December 31, 2022 and December 31, 2021. Subject to specified conditions, Gentherm can increase the Revolving Credit Facility or incur secured term loans in an aggregate amount of up to $ 200,000 . The Second Amended and Restated Credit Agreement extended the maturity of the Revolving Credit Facility from June 27, 2024 to June 10, 2027 . The outstanding principal and interest (of approximately $ 35,000 as of June 10, 2022) under the Amended and Restated Credit Agreement continued and remained obligations under the Second Amended and Restated Credit Agreement. The U.S. borrowers and guarantors participating in the Second Amended and Restated Credit Agreement also entered into a Second Amended and Restated Pledge and Security Agreement (the “Second Amended and Restated Security Agreement”). The Second Amended and Restated Security Agreement grants a security interest to the Agent in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Second Amended and Restated Security Agreement, including the stock and membership interests of specified subsidiaries (limited to 66 % of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Second Amended and Restated Credit Agreement (including all obligations of any U.S. or non-U.S. loan party) are unconditionally guaranteed by certain of Gentherm’s domestic subsidiaries, and the German subsidiary borrowers and certain other foreign subsidiaries guarantee all obligations of the non-U.S. loan parties under the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders. The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. The Second Amended and Restated Credit Agreement also contains customary events of default. As of December 31, 2022, the Company was in compliance with the terms of the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement additionally contains customary events of default. Upon the occurrence of an event of default, the amounts outstanding under the Revolving Credit Facility may be accelerated and may become immediately due and payable. Under the Second Amended and Restated Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Term SOFR rate (“Term SOFR Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate plus 0.50 %, Bank of America’s prime rate, or the Term SOFR rate plus 1.00 %. The rate for Term SOFR Rate Loans denominated in U.S. Dollars is equal to the forward-looking Secured Overnight Financing Rate (“SOFR”) term rate administered by the CME with a term of one month. All loans denominated in a currency other than the U.S. Dollar must be Term SOFR Rate Loans. Interest is payable at least quarterly. Additionally, a commitment fee of between 0.175 % to 0.300 %, which will vary based on the Consolidated Net Leverage Ratio, as defined in the Second Amended and Restated Credit Agreement, is payable on the average daily unused amounts under the Revolving Credit Facility. The Applicable Rate varies based on the Consolidated Net Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Second Amended and Restated Credit Agreement, the lowest and highest possible Applicable Rate is 1.125 % and 2.125 %, respectively, for Term SOFR Rate Loans and 0.125 % and 1.125 %, respectively, for Base Rate Loans. Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and the maximum Consolidated Net Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing four fiscal quarters calculated for purposes of the Consolidated Net Leverage Ratio, $ 264,904 remained available as of December 31, 2022 for additional borrowings under the Second Amended and Restated Credit Agreement subject to specified conditions that Gentherm currently satisfies. In connection with the Second Amended and Restated Credit Agreement, the Company incurred debt issuance costs of $ 1,417 , which have been capitalized and will be amortized into interest expense over the term of the credit facility. In addition, unamortized deferred debt issuance costs of $ 144 were written-off and recognized in Interest expense, net during the twelve months ended December 31, 2022. The scheduled principal maturities of our debt as of December 31, 2022 were as follows: U.S. Other Debt Total 2023 $ — $ 2,443 $ 2,443 2024 — 437 437 2025 — 148 148 2026 — 68 68 2027 232,000 — 232,000 Total $ 232,000 $ 3,096 $ 235,096

Pension and Other Post Retireme

Pension and Other Post Retirement Benefit Plans	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Pension and Other Post Retirement Benefit Plans	Note 10 — Pension and Other Post Retirement Benefit Plans The Company maintains a U.S. defined benefit pension plan covering its former Chief Executive Officer (“U.S. Plan”) and a German defined benefit pension plan covering certain retired executive employees of the Company’s wholly owned subsidiary, Gentherm GmbH (“German Plan”). The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2022, 2021 and 2020 were as follows: U.S. Plan German Plan Year Ended December 31, Year Ended December 31, 2022 2021 2020 2022 2021 2020 Net periodic benefit cost: Service cost $ — $ — $ — $ — $ — $ — Interest cost 56 42 85 92 91 88 Expected return on plan assets — — — ( 109 ) ( 120 ) ( 121 ) Amortization of prior service cost and actuarial loss 22 26 7 114 133 124 Net periodic benefit cost $ 78 $ 68 $ 92 $ 97 $ 104 $ 91 Assumptions: Discount rate 1.80 % 1.20 % 2.40 % 1.25 % 1.08 % 1.06 % Long-term return on assets N/A N/A N/A 2.90 % 2.90 % 3.10 % A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2022 and 2021 is as follows: U.S. Plan German Plan As of December 31, As of December 31, 2022 2021 2022 2021 Change in projected benefit obligation: Balance at beginning of year $ 3,446 $ 3,847 $ 8,102 $ 8,934 Interest cost 56 42 92 91 Paid pension distributions ( 342 ) ( 342 ) ( 281 ) ( 310 ) Actuarial (gain) loss ( 349 ) ( 101 ) ( 2,001 ) 9 Exchange rate impact — — ( 514 ) ( 622 ) Balance at end of year $ 2,811 $ 3,446 $ 5,398 $ 8,102 Change in plan assets: Balance at beginning of year — — 4,069 4,276 Actual return on plan assets — — 89 98 Contributions — — — 310 Paid pension distributions — — — ( 310 ) Exchange rate impact — — ( 240 ) ( 305 ) Balance at end of year $ — $ — $ 3,918 $ 4,069 Underfunded Status $ ( 2,811 ) $ ( 3,446 ) $ ( 1,480 ) $ ( 4,033 ) Balance sheet classification: Other current liabilities $ ( 342 ) $ ( 342 ) $ ( 314 ) $ ( 306 ) Pension benefit obligation ( 2,469 ) ( 3,104 ) ( 1,166 ) ( 3,727 ) Accumulated other comprehensive loss (pre-tax): Actuarial losses 205 575 965 3,288 Assumptions: Discount rate 4.65 % 1.80 % 4.10 % 1.25 % Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2023 are as follows: U.S Plan German Plan Actuarial losses $ - $ 22 The accumulated benefit obligations were as follows: U.S. Plan German Plan As of December 31, As of December 31, 2022 2021 2022 2021 Accumulated benefit obligation $ 2,811 $ 3,446 $ 5,398 $ 8,102 Interest costs are recognized in Selling, general and administrative expenses in the consolidated statements of income and actuarial gains and losses are included the consolidated balance sheet as part of Accumulated other comprehensive loss within shareholders’ equity. Actuarial gains or losses are amortized to Selling, general and administrative expense in the consolidated statements of income based on the average future life of the Plan using the corridor method. Prior service cost is included in Selling, general and administrative expenses in the consolidated statements of income. Plan assets – German Plan Plan assets are comprised of Gentherm GmbH’s pension insurance policies and are pledged to the beneficiaries of the German Plan. A market valuation technique, based on observable underlying insurance charges, is used to determine the fair value of the pension plan assets (Level 2). The expected return on plan assets assumption used to calculate Gentherm GmbH’s pension benefit obligation was determined using actual returns realized on plan assets in the prior year. Contributions We do no t expect contribu tions to be paid to the U.S. Plan or the German Plan during the next fiscal year. The schedule of future expected pension payments is as follows: Projected Pension Year U.S Plan German Plan 2023 $ 342 $ 311 2024 342 303 2025 342 294 2026 342 285 2027 342 274 2028-2031 1,710 2,732 Total $ 3,420 $ 4,199 Defined contribution plans The Company also sponsors defined contribution plans for eligible employees. On a discretionary basis, the Company matches a portion of the employee contributions and or makes additional discretionary contributions. Gentherm recognized costs of $ 1,984 , $ 1,724 and $ 1,275 related to contributions to its defined contribution plans during the years ended December 31, 2022, 2021 and 2020 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11 — Commitments and Contingencies Legal and other contingencies The Company may be subject to various legal actions and claims in the ordinary course of its business, including those arising out of breach of contracts, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these matters will not have a material adverse effect on its consolidated results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves. Product Liability and Warranty Matters In the event that the Company’s products fail to perform as expected or result in alleged bodily injury or property damage, our products may subject us to warranty claims and product liability. If any of our products are or are alleged to be defective, we may be required to participate in a recall or other corrective action involving such products. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims in the future or that it will not incur significant costs to defend such claims. The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including claims already filed by customers, the warranty accrual is adjusted quarterly to reflect management’s best estimate of future claims. The following is a reconciliation of the changes in accrued warranty costs: Year Ended December 31, 2022 2021 Balance at beginning of year $ 1,916 $ 2,391 Warranty opening balance from acquired entities 907 - Warranty claims paid ( 1,841 ) ( 2,164 ) Warranty expense for products shipped during the current period 1,584 1,813 Adjustments to warranty estimates from prior periods ( 274 ) ( 73 ) Adjustments due to currency translation 88 ( 51 ) Balance at end of year $ 2,380 $ 1,916 Other matters Purchase commitments for materials, supplies, services and capital expenditures, as part of the normal course of business, are generally consistent from year to year. Commitments for capital expenditures as of December 31, 2022 were $ 6,853 . In addition, due to supply shortages of semiconductors, the Company has entered into agreements with various suppliers to reserve the right to purchase certain semiconductor chips over rolling periods of 12 - 24 months, with volume commitments determined based on our anticipated production requirements. As of December 31, 2022 , the Company’s total commitments for these semiconductor chip agreements was $ 40,130 . Such agreements provide the Company with priority access to semiconductor chips as they become available, however, these agreements do not guarantee that our suppliers will meet the timing and quantities requested by Gentherm. All other purchase commitments as of December 31, 2022 were immaterial. Employees Approximately 31 % of the Company’s workforce are members of industrial trade unions and are employed under the terms of various labor agreements. In 2023, certain agreements will require a vote on the terms of their respective labor contracts. Management does not anticipate any significant difficulties with respect to the renewal of these agreements.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings per Share	Note 12 — Earnings Per Share Basic earnings per share are computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the diluted earnings per share, the treasury stock method is used in determining the number of shares assumed to be issued from the exercise of Common Stock equivalents. The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Year Ended December 31, 2022 2021 2020 Net income $ 24,441 $ 93,434 $ 59,690 Basic weighted average shares of Common Stock outstanding 33,126,202 33,085,732 32,666,025 Dilutive effect of stock options, restricted stock awards and restricted stock units 376,952 423,988 362,079 Diluted weighted average shares of Common Stock outstanding 33,503,154 33,509,720 33,028,104 Basic earnings per share $ 0.74 $ 2.82 $ 1.83 Diluted earnings per share $ 0.73 $ 2.79 $ 1.81 The following table represents Common Stock issuable upon the exercise of certain stock options that have been excluded from the diluted earnings calculation because the effect of their inclusion would be anti-dilutive. Year Ended December 31, 2022 2021 2020 Anti-dilutive securities share impact — — 12,000 See Note 17 for information about the Company’s different equity incentive plans.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Note 13 —Financial Instruments Derivative Financial Instruments The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong. The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The decision of whether and when to execute derivative financial instruments, along with the duration of the instrument, may vary from period to period depending on market conditions, the relative costs of the instruments and capacity to hedge. The duration is linked to the timing of the underlying exposure, with the connection between the two being regularly monitored. The Company does not enter into derivative financial instruments for speculative or trading purposes. Some derivative contracts do not qualify for hedge accounting; for other derivative contracts, we elect to not apply hedge accounting. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to AOCI in the consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency and copper commodity hedging instruments, if any, to cost of sales, in the consolidated statements of income. Cash flows associated with derivatives are reported in net cash provided by operating activities in the Company’s Consolidated Statements of Cash Flows. The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term. In the second quarter of 2022, the Company entered into a floating-to-fixed interest rate swap agreement with a notional amount of $ 100,000 . This interest rate swap is an undesignated hedge of the Company’s exposure to interest payment fluctuations on a portion of the Credit Facility borrowings that were drawn for the acquisitions of Alfmeier and Dacheng. The periodic changes in fair value are recognized in Interest expense, net. In the second and third quarter of 2022, the Company entered into forward contracts with a notional amount of $ 128,319 to hedge the foreign currency risk associated with the forecasted purchase of Alfmeier. These contracts matured and were settled in the third quarter of 2022. During the year ended December 31, 2022 the Company recognized expense of $ 3,806 in Foreign currency (loss) gain within the consolidated income statement. Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2022 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 40,063 Other current assets $ 3,791 Other current liabilities $ — $ 3,791 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,772 Other current liabilities $ — $ 2,772 Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2021 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 13,974 Other current assets $ 294 Other current liabilities $ — $ 294 Commodity hedges Level 2 $ 309 Other current assets $ 6 Other current liabilities $ — $ 6 Information related to the effect of derivative instruments in the consolidated statements of income is as follows: Year Ended December 31, Location 2022 2021 2020 Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Cost of sales – income $ 1,458 $ 1,609 $ ( 1,629 ) Other comprehensive (loss) income 3,496 ( 1,217 ) 272 Foreign currency loss — — ( 118 ) Total foreign currency derivatives $ 4,954 $ 392 $ ( 1,475 ) Commodity derivatives Cost of sales – income $ 19 $ 14 $ — Other comprehensive (loss) income ( 6 ) 6 — Total commodity derivatives $ 13 $ 20 $ — Derivatives Not Designated as Hedging Instruments Foreign currency derivatives Foreign currency (loss) gain $ ( 3,806 ) $ - $ - Total foreign currency derivatives $ ( 3,806 ) $ - $ - Interest rate contracts Interest income (expense), net $ 2,772 $ - $ - Total interest rate derivatives $ 2,772 $ - $ - The Com pany did no t incur any hedge ineffectiveness duri ng the years ended December 31, 2022 and 2021. Accounts Receivable Factoring The Company sells certain customer trade receivables under factoring arrangements with designated financial institutions. All current factoring arrangements were assumed through the acquisition of Alfmeier. Beginning January 1, 2023, our North American factoring agreement is not active and the parties are currently undergoing negotiations in the ordinary course of business. Certain transactions occur under non-recourse agreements and are accounted for as sales, and the cash proceeds are included in cash provided by operating activities. The remaining transactions occur under deferred purchase agreements, in which a portion of the purchase price for the receivables is paid by the bank purchasers to the Company in cash upon sale. The remaining portion is recorded as a deferred purchase receivable, which is paid to the Company as payments on the receivables that are collected by the financial institution from account debtors. Cash proceeds received upon the sale of the receivables to the financial institution are included in cash provided by operating activities and the cash proceeds received on the deferred purchase receivables are included in cash provided by investing activities. All factoring arrangements incorporate customary representations, including representations as to validity of amounts due, completeness of performance obligations and absence of commercial disputes. During the year ended December 31, 2022 , we sold trade receivables totaling $ 61,482 and incurred factoring fees of $ 180 . As of December 31, 2022, receivables of $ 19,108 had been factored and had not yet been paid by customers to the respective financial institutions and our availability under the receivables factoring agreements was $ 5,479 . The collective limit under our factoring arrangements as of December 31, 2022 was $ 24,142 .

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement	Note 14 — Fair Value Measurement Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques: Market : This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Income : This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations. Cost : This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost). The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below: Level 1 : Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 : Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability. Level 3 : Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Items Measured at Fair Value on a Recurring Basis Except for derivative financial instruments (see Note 13) and pension plan assets (see Note 10), the Company has no material financial assets and liabilities that are carried at fair value at December 31, 2022 and 2021. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value. Items Measured at Fair Value on a Nonrecurring Basis The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. On July 1, 2021 the Company acquired B&E for $ 2,827 . The purchase price was allocated to inventory (Level 2), property and equipment (Level 2) and other intangible assets (Level 3) based on their estimated fair values as of the acquisition date. The Company utilized a third-party to assist in the Level 3 fair value estimates of other intangible assets for recent acquisitions (see Note 4). The estimated fair values of these assets were based on third-party valuations and management’s estimates, generally utilizing income and market approaches. As of December 31, 2022, and December 31, 2021 , there were no other significant assets or liabilities measured at fair value on a non-recurring basis. Items Not Carried at Fair Value The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of December 31, 2022, and 2021, the carrying values of the indebtedness under the Company’s Credit Agreement were not materially different than their estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 9).

Equity

Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Equity	Note 15 — Equity Common Stock The Company is authorized to issue up to 59,991,000 shares, of which 55,000,000 shares shall be common stock, without par value, and 4,991,000 shall be Preferred Stock, without par value. As of December 31, 2022 , an aggregate of 33,202,082 shares of its common stock were issued and outstanding. As of December 31, 2022, the re are no pref erred stock shares issued or outstanding. The Company’s common stock is listed on the Nasdaq Global Select Market under the symbol, “THRM”, and has the following rights and privileges: ▪ Voting rights. All shares of the Company’s common stock have identical rights and privileges. With limited exceptions, holders of common stock are entitled to one vote for each outstanding share of common stock held of record by each shareholder on all matters properly submitted for the vote of the Company’s shareholders. ▪ Dividend rights . Subject to applicable law, any contractual restrictions and the rights of the holders of outstanding preferred stock, if any, holders of common stock are entitled to receive ratably such dividends and other distributions that the Company’s Board of Directors, in its discretion, declares from time to time. ▪ Liquidation rights . Upon the dissolution, liquidation or winding up of the Company, subject to the rights of the holders of outstanding preferred stock, if any, holders of common stock are entitled to receive ratably the assets of the Company available for distribution to the Company’s shareholders in proportion to the number of shares of common stock held by each shareholder. ▪ Conversion, Redemption and Preemptive Rights . Holders of common stock have no conversion, redemption, sinking fund, preemptive, subscription or similar rights. Stock Repurchase Program In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”) to commence upon expiration of the prior stock repurchase program on December 15, 2020. Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $ 150,000 of its issued and outstanding common stock over a three-year period, expiring December 15, 2023 . Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the year ended December 31, 2022 , the Company did not make any repurchases under the 2020 Stock Repurchase Program. The 2020 Stock Repurchase Program had $ 130,000 repurchase authorization remaining as of December 31, 2022 .

Reclassifications Out of Accumu

Reclassifications Out of Accumulated Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Reclassifications Out of Accumulated Other Comprehensive Income (Loss)	N ote 16 – Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Reclassification adjustments and other activities impacting accumulated other comprehensive income (loss) during the years ended December 31, 2022, 2021 and 2020 are as follows: Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 5 $ 154 $ ( 36,922 ) Other comprehensive income (loss) before reclassifications 2,341 ( 13,786 ) 13 4,954 ( 6,478 ) Income tax effect of other comprehensive income (loss) before reclassifications ( 621 ) ( 295 ) ( 3 ) ( 1,092 ) ( 2,011 ) Amounts reclassified from accumulated other comprehensive loss into net income 137 — ( 19 ) a ( 1,458 ) a ( 1,340 ) Income taxes reclassified into net income ( 31 ) — 4 289 262 Net current period other comprehensive income (loss) 1,826 ( 14,081 ) ( 5 ) 2,693 ( 9,567 ) Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ — $ 2,847 $ ( 46,489 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2020 $ ( 3,451 ) $ ( 12,637 ) $ — $ 1,106 $ ( 14,982 ) Other comprehensive income (loss) before reclassifications 512 ( 21,274 ) 20 392 ( 20,350 ) Income tax effect of other comprehensive income (loss) before reclassifications ( 71 ) ( 277 ) ( 4 ) ( 85 ) ( 437 ) Amounts reclassified from accumulated other comprehensive loss into net income 159 — ( 14 ) a ( 1,609 ) a ( 1,464 ) Income taxes reclassified into net income ( 42 ) — 3 350 311 Net current period other comprehensive income (loss) 558 ( 21,551 ) 5 ( 952 ) ( 21,940 ) Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 5 $ 154 $ ( 36,922 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. Defined Benefit Foreign Currency Commodity Hedge Derivatives Foreign Currency Total Balance at December 31, 2019 $ ( 3,371 ) $ ( 39,879 ) $ — $ 895 $ ( 42,355 ) Other comprehensive (loss) income before reclassifications ( 328 ) 27,147 — ( 1,751 ) 25,068 Income tax effect of other comprehensive (loss) income before reclassifications 117 95 — 381 593 Amounts reclassified from accumulated other comprehensive loss into net income $ 131 — — 2,023 a 2,154 Income taxes reclassified into net income — — — ( 442 ) ( 442 ) Net current period other comprehensive (loss) income ( 80 ) 27,242 — 211 27,373 Balance at December 31, 2020 $ ( 3,451 ) $ ( 12,637 ) $ — $ 1,106 $ ( 14,982 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. The Company expects all of the existing gains and losses related to foreign currency derivatives reported in Accumulated other comprehensive loss as of December 31, 2022 to be reclassified into earnings during the next twelve months. See Note 13 for additional information about derivative financial instruments and the effects from reclassification to net income.

Accounting for Stock Based Comp

Accounting for Stock Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Accounting for Stock Based Compensation	Note 17 — Accounting for Stock Based Compensation On May 16, 2013, the Compensation Committee of the Company’s Board of Directors (the “Board”) approved the Gentherm Incorporated 2013 Equity Incentive Plan (the “2013 Plan”), covering 3,500,000 shares of our Common Stock. The 2013 Plan was amended on May 19, 2017 to increase the number of available shares by 2,000,000 and further amended on May 21, 2020 to increase the number of available shares by 2,450,000 . The 2013 Plan permits the granting of various awards including stock options (including both nonqualified options and incentive options), stock appreciation rights (“SARs”), restricted stock and restricted stock units (“RSUs”), performance-based restricted stock units (“PSUs”) shares and certain other awards to employees, outside directors and consultants and advisors of the Company. As of December 31, 2022 , the Company had an aggregate of 2,216,324 shares of Common Stock available to issue under the 2013 Plan. All equity plans are administered by the Compensation and Talent Management Committee of the Board. During the three-year period ended December 31, 2022 , the Company has outstanding stock options, SARs, restricted stock awards and restricted stock units to employees, directors and consultants. These awards become available to the recipient upon the satisfaction of a vesting condition, either based on a period of service or based on the performance of a specific achievement. For equity-based awards with a service condition, the requisite service period typically ranges between three to four years for employees and consultants and one year for directors. As of December 31, 2022 , there were 320,449 PSUs outstanding. These awards cliff vest after three-years based on the Company’s achievement of either a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year a target three year cumulative Adjusted EBITDA (“Adjusted EBITDA”), as defined in the award agreement, or the Company’s relative total shareholder return (“TSR”), as defined in the award agreement, during a specific three-year measurement period. In each case, awards will be earned at 50 % of the target number of shares for achieving a minimum threshold or up to 200 % of the target number of shares for exceeding the target, with a linear adjustment between threshold and target or between target and stretch performance goals. All other outstanding, unvested equity-based awards were service based. Equity-based award vesting may be accelerated at the discretion of the Board under conditions specified in the 2013 Plan. Under FASB ASC Topic 718, the provisions of the PSUs that vest upon the achievement of relative TSR are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this portion award. A third party was engaged to complete a Monte Carlo simulation to account for the market condition. That simulation takes into account the beginning stock price of our common stock, the expected volatilities for the relative TSR comparator group, the expected volatilities for the Company’s stock price, correlation coefficients, the expected risk-free rate of return and the expected dividend yield of the Company and the comparator group. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the relative TSR feature. The grant date fair value of the other PSUs and RSUs are calculated as the closing price of our common stock as quoted on Nasdaq on the grant date multiplied by the number of shares subject to the award. Each of ROIC and Adjusted EBITDA is considered a performance condition and the grant-date fair value for ROIC PSUs and Adjusted EBITDA PSUs corresponds with management's expectation of the probable outcome of the performance condition as of the grant date. The total recognized and unrecognized stock-based compensation expense is as follows: Stock-Based Compensation Expense 2022 2021 2020 Unrecognized Stock-Based Compensation Expense at December 31, 2022 Remaining Weighted Average Vesting Period RSUs $ 5,551 $ 4,594 $ 3,137 $ 8,724 1.80 PSUs 954 5,535 3,361 6,745 1.97 Restricted Shares 888 1,198 1,495 419 0.42 SARs ( 794 ) 2,721 5,494 - - Stock options - 482 836 - - Total Stock-Based Compensation $ 6,599 $ 14,530 $ 14,323 $ 15,888 1.84 The related deferred tax (expense) benefit for the years ended December 31, 2022, 2021 and 2020 was $( 444 ), $ 2,725 , and $ 3,002 , respectively. If Gentherm were to realize expired share-based payment arrangements, they would be reported as a forfeit in the activity roll forward tables below. RSUs The following table summarizes restricted stock unit activity during the years ended December 31, 2022, 2021 and 2020: Unvested Restricted Stock Units Time Vesting Weighted-Average Outstanding at December 31, 2019 141,741 $ 42.16 Granted 132,864 34.41 Vested ( 50,953 ) 42.13 Forfeited ( 14,747 ) 39.16 Outstanding at December 31, 2020 208,905 $ 37.26 Granted 93,539 79.79 Vested ( 88,296 ) 38.49 Forfeited ( 20,522 ) 48.76 Outstanding at December 31, 2021 193,626 $ 56.02 Granted 117,507 66.86 Vested ( 95,692 ) 49.85 Forfeited ( 13,863 ) 70.52 Outstanding at December 31, 2022 201,578 $ 64.27 The total intrinsic value of restricted stock units vested during the years ended December 31, 2022, 2021 and 2020 was $ 4,774 , $ 3,398 and $ 2,214 , respectively. PSUs The following table summarizes performance stock unit activity during the years ended December 31, 2022, 2021 and 2020: Unvested Performance Stock Units Relative TSR Target Weighted-Average ROIC Target Weighted-Average Adjusted EBITDA Target Shares Weighted-Average Total Outstanding at December 31, 2019 95,041 $ 61.77 95,039 $ 42.78 — $ — 190,080 Granted 77,967 49.25 77,967 33.72 — — 155,934 Vested — — — — — — — Forfeited ( 15,090 ) 56.84 ( 15,090 ) 39.96 — — ( 30,180 ) Outstanding at December 31, 2020 157,918 $ 56.06 157,916 $ 38.58 — $ — 315,834 Granted 20,626 118.08 40,580 78.98 39,930 79.49 101,136 Performance Adjustment 30,828 69.18 ( 30,830 ) 44.92 — — ( 2 ) Vested ( 61,656 ) 69.18 — — — — ( 61,656 ) Forfeited ( 16,148 ) 61.10 ( 17,374 ) 44.32 ( 2,454 ) 79.49 ( 35,976 ) Outstanding at December 31, 2021 131,568 $ 62.09 150,292 $ 47.52 37,476 $ 79.49 319,336 Granted 21,324 103.31 42,640 68.63 42,640 68.63 106,604 Performance Adjustment 45,004 57.46 ( 2,258 ) 41.61 — — 42,746 Vested ( 90,371 ) 57.46 ( 43,106 ) 41.61 — — ( 133,477 ) Forfeited ( 4,724 ) 68.67 ( 6,493 ) 56.87 ( 3,543 ) 75.10 ( 14,760 ) Outstanding at December 31, 2022 102,801 $ 65.20 141,075 $ 55.18 76,573 $ 73.66 320,449 The total intrinsic value of performance stock units vested during the years ended December 31, 2022, 2021 and 2020 was $ 6,986 , $ 4,265 and $ 0 , respectively. Restricted Shares The following table summarizes restricted stock activity during the years ended December 31, 2022, 2021 and 2020: Unvested Restricted Shares Shares Weighted-Average Outstanding at December 31, 2019 34,920 $ 38.31 Granted 32,406 39.96 Vested ( 32,420 ) 38.33 Forfeited — — Outstanding at December 31, 2020 34,906 $ 39.82 Granted 13,742 70.18 Vested ( 37,272 ) 41.70 Forfeited — — Outstanding at December 31, 2021 11,376 $ 70.33 Granted 13,600 73.54 Vested ( 11,376 ) 70.33 Forfeited — — Outstanding at December 31, 2022 13,600 $ 73.54 The compensation cost associated with restricted shares is estimated on the date of grant using quoted market prices (Level 1 input). The total fair value of restricted shares vested in 2022, 2021 and 2020 was $ 800 , $ 1,554 and $ 1,499 , respectively. SARs The following table summarizes SARs activity during the years ended December 31, 2022, 2021 and 2020: Stock Appreciation Rights Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2019 554,250 $ 39.41 2.84 $ 2,981 Granted — — Exercised ( 342,150 ) 38.22 Forfeited ( 40,500 ) 44.39 Outstanding at December 31, 2020 171,600 $ 40.60 2.44 $ 4,224 Granted — — Exercised ( 116,000 ) 40.34 Forfeited — — Outstanding at December 31, 2021 55,600 $ 41.15 1.28 $ 2,544 Granted — — Exercised ( 40,850 ) 42.27 Forfeited — — Outstanding at December 31, 2022 14,750 $ 38.05 1.15 $ 402 Exercisable at December 31, 2022 14,750 $ 38.05 1.15 $ 402 There have been no SAR s granted since the year ended December 31, 2017 and all SARs are currently vested. The total intrinsic value of SARs exercised during the years ended December 31, 2022, 2021 and 2020 was $ 1,348 , $ 4,301 and $ 4,164 , respectively. Stock Options The following table summarizes stock option activity during the years ended December 31, 2022, 2021 and 2020: Options Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2019 869,000 $ 37.87 3.51 $ 5,172 Granted — — Exercised ( 434,250 ) 38.12 Forfeited ( 6,750 ) 38.05 Outstanding at December 31, 2020 428,000 $ 37.61 3.20 $ 11,815 Granted — — Exercised ( 215,250 ) 38.46 Forfeited ( 6,000 ) 38.05 Outstanding at December 31, 2021 206,750 $ 36.72 2.60 $ 10,375 Granted — — Exercised ( 44,116 ) 37.87 Forfeited - - Outstanding at December 31, 2022 162,634 $ 36.41 2.68 $ 8,212 Exercisable at December 31, 2022 162,634 $ 36.41 2.68 $ 8,212 There have been no stock options granted since the year ended December 31, 2017 and all stock options are currently vested. The total intrinsic value of stock options exercised during the years ended December 31, 2022, 2021 and 2020 was $ 1,582 , $ 8,269 and $ 5,317 , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 18 — Income Taxes The income tax provisions were calculated based upon the following components of earnings before income tax for the years ended December 31, 2022, 2021 and 2020: Year Ended December 31, 2022 2021 2020 Earnings before income tax: Domestic $ ( 34,211 ) $ ( 4,547 ) $ ( 11,374 ) Foreign 72,593 118,399 92,930 Earnings before income tax $ 38,382 $ 113,852 $ 81,556 The components of the provision for income taxes for the years ended December 31, 2022, 2021 and 2020 are summarized as follows: Year Ended December 31, 2022 2021 2020 Current income tax expense: Federal $ 3,006 $ 1,944 $ 784 State and local 650 234 83 Foreign 17,607 18,390 20,150 Total current income tax expense $ 21,263 20,568 21,017 Deferred income tax (benefit) expense: Federal ( 5,971 ) ( 4,400 ) ( 2,302 ) State and local ( 213 ) ( 91 ) 32 Foreign ( 1,138 ) 4,341 3,119 Total deferred (benefit) income tax expense ( 7,322 ) ( 150 ) 849 Total income tax expense $ 13,941 $ 20,418 $ 21,866 As of December 31, 2022 , deferred U.S. income taxes have not been provided on the undistributed earnings of the Company’s foreign subsidiaries since these earnings will not be taxable upon repatriation to the United States. These earnings will be primarily treated as previously taxed income from either the one-time transition tax or global intangible low-taxed income (“GILTI”) provision, or they will be offset with a 100 % dividend received deduction. However, the Company continues to provide a deferred tax liability for foreign income and withholding tax that will be incurred with respect to the undistributed foreign earnings that are not indefinitely reinvested. The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2022 and 2021: December 31, 2022 2021 Deferred tax assets: Net operating losses $ 43,296 $ 25,610 Intangible assets 4,417 21,179 Research and development credits 7,835 9,736 Property and equipment 6,983 7,071 Valuation reserves and accrued liabilities 8,388 7,333 Capitalized Research and Development Costs 19,087 9,018 Stock compensation 3,051 3,832 Defined benefit obligation 1,265 1,466 Inventory 6,762 1,914 Other credits 10,296 10,158 Other 790 146 Total deferred tax asset 112,170 97,463 Valuation allowance ( 36,671 ) ( 16,090 ) Deferred tax liabilities: Unrealized foreign currency exchange gains $ ( 2,413 ) $ ( 2,488 ) Undistributed profits of subsidiary ( 5,981 ) ( 6,676 ) Property and equipment ( 15,423 ) ( 2,420 ) Other ( 3,056 ) ( 1,428 ) Total deferred tax liability ( 26,873 ) ( 13,012 ) Net deferred tax asset $ 48,626 $ 68,361 Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2022, 2021 and 2020 are as follows: Year Ended December 31, 2022 2021 2020 Statutory Federal income tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) resulting from: Change in valuation allowance 6.4 % ( 1.2 )% ( 0.4 )% Effect of different tax rates of foreign jurisdictions ( 4.9 )% ( 5.2 )% ( 4.7 )% Tax credits & deductions related to R&D ( 10.1 )% ( 2.3 )% ( 3.8 )% Non-deductible expenses 14.9 % 1.7 % 2.1 % Non-deductible expenses related to acquisitions 7.0 % 0.0 % 0.0 % Other foreign, state and local taxes 0.7 % 1.6 % 1.4 % Tax impact of foreign income 4.2 % 3.6 % 4.9 % Stock option compensation ( 3.8 )% ( 2.0 )% ( 0.4 )% Other 0.9 % 0.7 % 6.7 % Effective rate 36.3 % 17.9 % 26.8 % The Company has Net Operating Loss (“NOL”) carryforwards as follows: Jurisdiction Amount as of December 31, 2022 Years of Expiration U.S. state income tax $ 54,912 2023 - 2042 Foreign $ 320,417 Indefinite We have NOL carryforwards in various states associated with the benefits of the state dividends received reduction and foreign royalty exclusion. The state NOL carryforwards generally expire at various dates from 2023 to 2042 . We have concluded that there is not sufficient evidence these NOL carryforwards will be utilized, and thus have not recognized the benefit of these NOL carryforwards. At December 31, 2022 , certain non-U.S. subsidiaries had NOL carryforwards totaling $ 320,417 which have no expiration date . The Company has a valuation allowance recorded against $ 133,877 of the total non-U.S. subsidiaries’ net operating loss carryforwards as of December 31, 2022. The Company is subject to taxation in the United States and various state and foreign jurisdictions. As of December 31, 2022, the Company was no longer subject to U.S. Federal examinations by tax authorities for tax years before 2019 and was no longer subject to foreign examinations by tax authorities for tax years before 2014. The Company currently benefits from tax holidays in various non-U.S. jurisdictions with expiration dates from 2024 – 2025. The amount of corporate income tax savings realized by the Company as a result of the tax holidays during the current and prior years was immaterial as a result of operating losses previously generated. At December 31, 2022, 2021 and 2020, the Company had total unrecognized tax benefits of $ 6,185 , $ 5,665 and $ 4,967 , respectively, all of which, if recognized, would affect the effective income tax rates. The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, 2022 2021 2020 Balance at beginning of year $ 5,665 $ 4,967 $ 3,795 Additions based on tax position related to current year 972 1,105 1,489 Additions based on tax position related to prior year 433 160 179 Reductions from settlements and statute of limitation expiration ( 610 ) ( 312 ) $ ( 650 ) Effect of foreign currency translation ( 275 ) ( 255 ) 154 Balance at end of year $ 6,185 $ 5,665 $ 4,967 The Company classifies income tax-related penalties and net interest as income tax expense. In the years ended December 31, 2022, 2021 and 2020 , income tax related interest and penalties were not material. It is reasonably possible that audit settlements, the conclusions of current examinations or the expiration of the statute of limitations in several jurisdictions could impact the Company’s unrecognized tax benefits.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Reporting	Note 19 — Segment Reporting Segment information is used by management for making operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss. The Company’s reportable segments are as follows: • Automotive — this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, battery performance solutions, lumbar and massage comfort solutions, valve system technologies, and automotive electronic and software systems. • Medical — this segment represents the results from our patient temperature management business within the medical industry. The Corporate category includes unallocated costs related to our corporate headquarter activities, including selling, general and administrative costs and acquisition transaction costs, which do not meet the requirements for being classified as an operating segment. The tables below present segment information about the reported product revenues and operating income of the Company for years ended December 31, 2022, 2021 and 2020. With the exception of goodwill, asset information by segment is not reported since the Company does not manage assets at a segment level. Automotive Medical Corporate Total 2022: Product revenues $ 1,161,616 $ 43,040 $ — $ 1,204,656 Depreciation and amortization 39,815 3,344 1,235 44,394 Operating income (loss) 118,433 ( 4,029 ) ( 66,097 ) 48,307 2021: Product revenues $ 1,004,633 $ 41,517 $ — $ 1,046,150 Depreciation and amortization 35,389 2,460 931 38,780 Operating income (loss) 162,994 ( 1,829 ) ( 46,159 ) 115,006 2020: Product revenues $ 869,998 $ 43,100 $ — $ 913,098 Depreciation and amortization 37,662 2,366 1,086 41,114 Operating income (loss) 138,410 971 ( 50,164 ) 89,217 Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2022, 2021 and 2020 are as follows: Year Ended December 31, 2022 2021 2020 Climate Control Seat $ 426,046 $ 393,816 $ 342,550 Seat Heaters 283,970 270,054 249,665 Steering Wheel Heaters 120,949 102,496 76,272 Automotive Cables 76,962 84,114 73,997 Battery Performance Solutions 71,907 69,594 50,901 Electronics 44,106 51,648 53,238 Lumbar and Massage Comfort Solutions (a) 56,980 — — Valve System Technologies (a) 41,980 — — Other Automotive 38,716 32,911 23,375 Subtotal Automotive segment 1,161,616 1,004,633 869,998 Medical segment (a) 43,040 41,517 43,100 Total Company $ 1,204,656 $ 1,046,150 $ 913,098 (a) Includes product revenues from acquisitions since their respective acquisition dates (see Note 4). Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2022, 2021 and 2020 is as follows: Year Ended December 31, 2022 2021 2020 United States $ 472,468 $ 404,466 $ 377,577 China 183,419 142,816 101,039 South Korea 94,937 93,516 88,745 Germany 75,367 66,929 58,536 Japan 57,718 63,527 57,785 Czech Republic 49,293 43,931 37,542 Romania 47,532 51,367 33,147 Slovakia 34,686 30,004 21,568 Finland 33,627 29,325 15,958 Mexico 23,233 18,194 13,429 Other 132,376 102,075 107,772 Total Non-U.S. 732,188 641,684 535,521 Total Company $ 1,204,656 $ 1,046,150 $ 913,098 The table below lists the percentage of total product revenues generated from sales to customers which contributed 10% or more to the Company’s total consolidated product revenue for the years ended December 31, 2022, 2021 and 2020: Year Ended December 31, 2022 2021 2020 Lear 16 % 15 % 15 % Adient 15 % 15 % 14 % Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2022 and 2021 is as follows: December 31, Property and equipment, net 2022 2021 Germany $ 47,342 $ 16,174 China 43,162 25,411 United States 41,034 19,222 Mexico 31,597 20,296 North Macedonia 27,808 32,682 Vietnam 19,808 19,876 Czech Republic 11,381 — Hungary 11,736 8,995 Ukraine 5,077 9,539 Other 5,535 3,075 Total $ 244,480 $ 155,270

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2022
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS For the Years Ended December 31, 2022, 2021 and 2020 (In thousands) Description Balance at Charged to Other Activity Deductions Balance at Allowance for Doubtful Accounts Year Ended December 31, 2020 $ 1,193 $ 1,298 $ 33 $ ( 1,363 ) $ 1,161 Year Ended December 31, 2021 1,161 1,066 ( 12 ) ( 816 ) 1,399 Year Ended December 31, 2022 1,399 1,088 — ( 1,267 ) 1,220 Allowance for Deferred Income Tax Assets Year Ended December 31, 2020 $ 17,316 — $ 139 $ ( 258 ) $ 17,197 Year Ended December 31, 2021 17,197 357 ( 102 ) ( 1,362 ) 16,090 Year Ended December 31, 2022 16,090 2,482 18,099 a - 36,671 Reserve for Inventory Year Ended December 31, 2020 $ 6,073 $ 1,768 $ 214 $ ( 914 ) $ 7,141 Year Ended December 31, 2021 7,141 2,499 ( 134 ) ( 3,492 ) 6,014 Year Ended December 31, 2022 6,014 15,923 ( 133 ) ( 2,558 ) 19,246 (a) Includes amount relates to valuation allowance from acquisitions .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20 %), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Intercompany transactions and balances between consolidated businesses have been eliminated.
Use of Estimates	Use of Estimates In preparing these consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.
Business combinations	Business combinations In accordance with ASC Topic 805, “Business Combinations,” acquisitions are recorded using the acquisition method of accounting. The Company includes the operating results of acquired entities from their respective dates of acquisition. The Company recognizes and measures the identifiable assets acquired, liabilities assumed, and any non-controlling interest as of the acquisition date fair value. The excess, if any, of total consideration transferred in a business combination over the fair value of identifiable assets acquired, liabilities assumed and any non-controlling interest is recognized as goodwill. Costs incurred as a result of a business combination other than costs related to the issuance of debt or equity securities are recorded in the period the costs are incurred. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to assets acquired and liabilities assumed with the corresponding offset to goodwill.
Segment Reporting	Segment Reporting The Company has two reportable segments: Automotive and Medical . The Automotive reporting segment is comprised of the results from our global automotive businesses, including the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, lumbar and massage comfort solutions, valve system technologies, battery performance solutions, and automotive electronic and software systems. The Medical reporting segment is comprised of the results from the patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute care, ambulatory, clinics and home health.
Revenue Recognition	Revenue Recognition Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from Product revenues. Shipping and handling fees billed to customers are included in Product revenues, while costs of shipping and handling are included in Cost of sales. Automotive Revenues The Company provides production parts to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, a LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from its customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts. Certain LTAs provide for annual price reductions over the production life of the vehicle. Agreements that are determined to provide customers with purchase option discounts that would not be received without entering into the contract are considered to contain a material right (for example, a discount given to a customer that is incremental to the range of discounts typically given to that class of customer). The material right represents a purchase option that provides the customer with the ability to purchase additional production parts at a set price in the future and is accounted for as a separate performance obligation. Under these circumstances, each transfer of production parts under the LTA requires allocation of the purchase price to the production part and the purchase option. As a practical alternative to estimating the standalone selling price of an option, the Company allocates transaction price to the purchase option by reference to the production part volumes expected to be ordered and the consideration expected to be received over the life of the vehicle program. The production part’s relative standalone selling price observed under the LTA is subtracted from the total amount of consideration expected to be received in exchange for transferring of parts under the current contract and the difference is allocated to the purchase option. Revenue from options containing a material right is recognized when the amounts billed to the customer for production parts transferred, under the LTA, is less than the standalone selling price of those production parts. Medical Revenues Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on body and blood temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized at the point in time the medical products or equipment is transferred to the customer. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company has no material contract assets or contract liabilities as of December 31, 2022. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year . Total capitalized costs to obtain a contract were $ 2,239 and $ 1,946 as of December 31, 2022 and 2021, respectively. These amounts are recorded in Other non-current assets and are being amortized into Product revenues over the expected production life of the applicable program. During the year ended December 31, 2022 and 2021 , $ 78 and $ 174 , respectively, was amortized into Product revenues.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. Cash balances in individual banks may exceed the federally insured limit by the Federal Deposit Insurance Corporation. The Company had Cash and cash equivalents of $ 108,620 and $ 161,496 held in foreign jurisdictions as of December 31, 2022 and 2021 , respectively.
Disclosures About Fair Value of Financial Instruments	Disclosures About Fair Value of Financial Instruments The carrying amounts of financial instruments comprising cash and cash equivalents, short-term investments, accounts receivable, notes receivable and accounts payable approximate fair value because of the short maturities of these instruments. The carrying amount of the Company’s revolving credit note under the June 10, 2022 amended and restated credit agreement (“Credit Agreement”) approximates its fair value because interest charged on the loan balance is variable. See Note 14, “Fair Value Measurement,” for information about the techniques used to assess the fair value of financial assets and liabilities, including our fixed rate debt instruments.
Concentration of Credit Risk	Concentration of Credit Risk Financial assets, which subject the Company to concentration of credit risk, consist primarily of cash equivalents, short-term investments, accounts receivable and notes receivable. Cash equivalents consist primarily of money market funds managed by major financial services companies. The credit risk for these cash equivalents is considered low. The Company does not require collateral from its customers. As of December 31, 2022 , the Company’s Automotive customers, Adient and Lear both individually represented 18 % and 17 %, respectively, of the Company’s accounts receivable balance. As of December 31, 2021 , the Company’s Automotive customers, Adient and Lear both individually represented 22 % and 18 %, respectively, of the Company’s accounts receivable balance.
Accounts Receivable	Accounts Receivable Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company determines the allowances based on historical write-off experience by industry and regional economic data, current expectations of future credit losses and historical cash discounts. The Company’s accounts receivables are continually assessed for collectability and any allowance is recorded based upon the age of outstanding receivables, historical payment experience and customer creditworthiness. We write-off accounts receivable when they become uncollectible. The allowance for doubtful accounts was $ 1,220 and $ 1,399 as of December 31, 2022 and 2021, respectively. The reconciliation of the beginning and ending amount of the allowance for doubtful accounts is as follows: Year Ended December 31, 2022 2021 2020 Balance at beginning of year $ 1,399 $ 1,161 $ 1,193 Charged to costs and expenses 1,088 1,066 1,298 Other activity - ( 12 ) 33 Deductions from reserves ( 1,267 ) ( 816 ) ( 1,363 ) Balance at end of year $ 1,220 $ 1,399 $ 1,161 Primarily in the Asia-Pacific region, the Company receives bank notes from certain customers to settle trade receivables. The collection of such bank notes is included in operating cash flows based on the substance of the underlying transactions, which are operating in nature. Bank notes held by the Company are classified as notes receivable within other current assets. The Company may hold such bank notes until maturity, exchange them with suppliers to settle liabilities, or sell them to third-party financial institutions in exchange for cash.
Inventory	Inventory The Company’s inventory is measured at the lower of cost or net realizable value. Raw materials, components and consumables are measured using the weighted average cost method. Work-in-process and finished goods are measured using the first-in first-out method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months' supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve.
Property and Equipment	Property and Equipment Property and equipment, including additions and improvements, are recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as Operating income or expense. The Company evaluates the recoverability of long-lived assets when events and circumstances indicate that the assets may be impaired and the undiscounted net cash flows estimated to be generated by those assets are less than their carrying value. If the net carrying value exceeds the fair value, an impairment loss exists and is calculated based on either estimated salvage value or estimated orderly liquidation value. Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years The Company recognized depreciation expense of $ 33,730 , $ 29,622 and $ 31,037 for the years ended December 31, 2022, 2021 and 2020 , respectively.
Tooling	Tooling The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in Other current assets in the accompanying consolidated balance sheets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2022 and 2021 , the Company had $ 15,267 and $ 3,778 , respectively, of reimbursable tooling costs capitalized. Company-owned tooling is included in Property and equipment and depreciated over its expected useful life, generally two to ten years .
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition. Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 12 years Product development costs 5 to 10 years Trade names Indefinite Software development costs 4 to 5 years Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. All costs associated with the development and issuance of new patents are expensed as incurred. Such costs are classified as research and development expenses in the accompanying consolidated statements of income.
Impairments of Other Intangible Assets and Goodwill	Impairments of Other Intangible Assets and Goodwill Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized. The Company utilizes an income approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in our industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect a risk factor, if necessary. Other significant assumptions include terminal value growth rates and terminal value margin rates. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income approach provides a reasonable estimate of the fair value of a reporting unit. The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount.
Investments in Non-Consolidated Affiliates	Investments in non-consolidated affiliates During 2021, the Company’s Automotive segment invested $ 5,200 for an ownership interest in Carrar Ltd. (“Carrar”), an Israel-based technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. During 2021, the Company’s Automotive segment invested $ 2,357 for an ownership interest in Forciot Oy (“Forciot”), a Finland-based technology developer of sensors for touch, motion and force measurement. Gentherm’s investment in Forciot is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in Other non-current assets. In December 2021, the Company committed to make a $ 5,000 investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten-year life of the fund. The Company has made contributions totaling approximately $ 495 to the Autotech Fund III, LP as of December 31, 2022. This fund focuses broadly on the automotive industry and compliments the Company’s innovation strategy.
Research and Development Expenses	Research and Development Expenses Research and development activities are expensed as incurred. The Company groups development and prototype costs and related reimbursements in research and development.
Leases	Leases The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles. Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 9 years and may include options to extend the lease. Land leases have remaining lease terms that range from 3 to 40 years and some which specify that the end of the lease term is at the discretion of the lessee. We do not have lease arrangements with related parties. The Company determines whether a contractual arrangement is or contains a lease at inception. Leases that are operating in nature are recognized in Operating lease right-of-use assets, Current lease liabilities and Non-current lease liabilities in the accompanying consolidated balance sheets. Finance leases are included in property and equipment, net, current maturities of long-term debt, and long-term debt on the Company’s consolidated balance sheets. Lease liabilities are measured initially at the present value of the sum of the future minimum rental payments at the commencement date of the lease. Lease payments that will vary in the future due to changes in facts and circumstances are excluded from the calculation of rental payments, unless those variable payments are based on an index or rate. Rental payments are discounted using an incremental borrowing rate, unless there is a rate implicit in the lease agreement. The incremental borrowing rate is based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). Judgment is used to assess the importance of risk factor inputs during the computation of the Company’s credit rating. For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate. Operating lease right-of-use assets are measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments, lease incentive received, and initial direct costs incurred, as applicable. Periods covered by an option to extend the lease are initially included in the measurement of an operating lease right-of-use asset and lease liability only when it is reasonably certain we will exercise the option. Gentherm’s lease agreements do not contain residual value guarantees or impose restrictions or covenants on the Company. For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income.
Income Taxes	Income Taxes The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2022 and 2021, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized. If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in Income tax expense.
Derivative Financial Instruments - Hedge Accounting	Derivative Financial Instruments – Hedge Accounting All derivative instruments are required to be reported on the balance sheet at fair value unless the transactions qualify and are designated as normal purchases or sales. Changes in fair value are reported currently through earnings unless they meet hedge accounting criteria. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. The Company accounts for its designated derivative financial instruments as cash flow hedges. For derivative contracts which are designated as a cash flow hedge, the effective portion of the change in the fair value of the derivative contract is recorded to Accumulated other comprehensive loss (“AOCI”) in the accompanying consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in AOCI is recorded into earnings in the accompanying consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. Any ineffective portion of the gain or loss is recognized in the accompanying consolidated statements of income under Foreign currency gain (loss) for foreign currency derivatives, and cost of goods sold for commodity derivatives. These hedging transactions and the respective correlations meet the requirements for hedge accounting. Exposure to fluctuations in interest rates and certain commodity prices are managed by entering into swaps with various counterparties. The Company does not enter into derivative transactions for speculative or trading purposes. As part of the hedging program approval process, Gentherm identifies the specific financial risk which the derivative transaction will minimize, the appropriate hedging instrument to be used to reduce the risk and the correlation between the financial risk and the hedging instrument. Hedge positions, as well as the correlation between the transaction risks and the hedging instruments, are reviewed on an ongoing basis.
Earnings Per Share	Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the respective period. The Company’s diluted earnings per share give effect to all potential shares of common stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of common stock equivalents.
Stock Based Compensation	Stock Based Compensation Share based payments that involve the issuance of common stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the consolidated financial statements as compensation expense based upon the fair value on the date of grant. Share based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements Not Yet Adopted	Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting”. ASU 2020-04 provides practical expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The expedients and exceptions provided by the amendments in this update apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate or another reference rate expected to be discontinued as a result of reference rate reform. These amendments are not applicable to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022. In January 2021, the FASB subsequently issued ASU 2021-01, “Reference Rate Reform (Topic 848): Scope” to clarify that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. ASU 2020-04 and ASU 2021-01 are effective as of March 12, 2020 through December 31, 2022 and may be applied retrospectively to contract modifications and hedging relationships from the beginning of an interim period that includes or is subsequent to March 12, 2020, or on a prospective basis to new modifications from any date within an interim period that includes or is subsequent to the date of the issuance of a final update, up to the date that financial statements are available to be issued. Upon adoption of this standard, the Company does not expect it to have a material impact to the Company’s financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Allowance for Doubtful Accounts	The reconciliation of the beginning and ending amount of the allowance for doubtful accounts is as follows: Year Ended December 31, 2022 2021 2020 Balance at beginning of year $ 1,399 $ 1,161 $ 1,193 Charged to costs and expenses 1,088 1,066 1,298 Other activity - ( 12 ) 33 Deductions from reserves ( 1,267 ) ( 816 ) ( 1,363 ) Balance at end of year $ 1,220 $ 1,399 $ 1,161
Estimated Useful Lives of Property and Equipment	Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s Property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years
Fair Value and Corresponding Useful Lives for Acquired Intangibles Assets	Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 12 years Product development costs 5 to 10 years Trade names Indefinite Software development costs 4 to 5 years

Restructuring and Impairments (

Restructuring and Impairments (Tables)	12 Months Ended
	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Summary of Restructuring Expense by Reportable Segment	Restructuring expense by reporting segment for the years ended December 31, 2022, 2021 and 2020 was as follows: Year Ended December 31, 2022 2021 2020 Automotive $ 637 $ 2,793 $ 5,075 Medical — — 112 Corporate — 1,064 616 Total $ 637 $ 3,857 $ 5,803
Summary of Restructuring Activity for All Restructuring Initiatives	The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2022 and 2021: Employee Separation Costs Other Related Costs Total Balance at December 31, 2020 $ 5,627 $ — $ 5,627 Additions, charged to restructuring expenses 2,406 1,927 4,333 Change in estimate ( 214 ) ( 262 ) ( 476 ) Cash payments ( 6,129 ) ( 1,709 ) ( 7,838 ) Non-cash utilization — ( 218 ) ( 218 ) Currency translation and other ( 196 ) 262 66 Balance at December 31, 2021 $ 1,494 $ — $ 1,494 Additions, charged to restructuring expenses 6 581 587 Change in estimate 50 — 50 Cash payments ( 881 ) ( 581 ) ( 1,462 ) Currency translation and other ( 81 ) — ( 81 ) Balance at December 31, 2022 $ 588 $ — $ 588

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2022
Alfmeier
Business Acquisition [Line Items]
Summary of Product Revenues and Operating Income	The following table provides product revenues and operating income from Alfmeier that are included in our consolidated financial statements: Year Ended December 31, 2022 Product revenues $ 98,960 Net loss ( 2,675 )
Summary of Purchase Consideration to Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the purchase consideration to the fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments: Initial Allocation Measurement Period Adjustments Revised Allocation Purchase price, consideration, net of cash acquired (a) $ 164,887 $ 5,813 $ 170,700 — Accounts receivable 24,988 ( 121 ) 24,867 Inventory 36,026 ( 106 ) 35,920 Prepaid expenses and other assets 20,920 ( 74 ) 20,846 Operating lease right-of-use assets 4,608 — 4,608 Property and equipment 89,942 1,242 91,184 Other intangible assets 22,668 8,791 31,459 Goodwill 43,678 ( 9,184 ) 34,494 Assumed liabilities ( 55,994 ) 975 ( 55,019 ) Deferred tax liabilities ( 21,949 ) 4,290 ( 17,659 ) Net assets acquired $ 164,887 $ 5,813 $ 170,700 (a) Purchase price includes cash paid of $ 170,439 plus amounts due to seller of $ 261 .
Summary of Allocation of Purchase Consideration to Other Intangible Assets Acquired	The following table summarizes the allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 19,812 14 Technology 11,647 9 Total $ 31,459
Summary of Unaudited Pro Forma Information	The following unaudited pro forma information represents our product revenues and net income as if the acquisition of Alfmeier had occurred as of January 1, 2021: Year Ended December 31, 2022 2021 Product revenues $ 1,348,295 $ 1,304,505 Net Income 17,645 92,079
Dacheng
Business Acquisition [Line Items]
Summary of Product Revenues and Operating Income	The results of Dacheng's operations are reported within the Medical segment from the date of acquisition. The following table provides product revenues and operating income from Dacheng that are included in our consolidated financial statements: Year Ended December 31, 2022 Product revenues $ 3,499 Net Loss ( 217 )
Summary of Purchase Consideration to Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the purchase consideration to the fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments: Initial Allocation Measurement Period Adjustments Revised Allocation Purchase price, cash consideration, net of cash acquired $ 35,048 $ — $ 35,048 — Accounts receivable 746 ( 84 ) 662 Inventory 1,942 ( 177 ) 1,765 Prepaid expenses and other assets 152 22 174 Operating lease right-of-use assets 841 — 841 Property and equipment 684 — 684 Other intangible assets 19,094 965 20,059 Goodwill 22,995 ( 3,979 ) 19,016 Assumed liabilities ( 2,799 ) ( 40 ) ( 2,839 ) Deferred tax liabilities ( 8,607 ) 3,293 ( 5,314 ) Net assets acquired $ 35,048 $ — $ 35,048
Summary of Allocation of Purchase Consideration to Other Intangible Assets Acquired	The following table summarizes the allocation of the purchase consideration to the other intangible assets acquired: Preliminary Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 12,837 12 Technology 4,749 12 Indefinite-lived: Tradenames 2,473 — Total $ 20,059

Details of Certain Financial _2

Details of Certain Financial Statement Components (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Statement Components [Abstract]
Details of Certain Financial Statement Components	December 31, 2022 2021 Inventory: Raw materials, net of reserve $ 136,217 $ 96,426 Work in process, net of reserve 17,695 9,495 Finished goods, net of reserve 64,336 53,556 Total inventory, net $ 218,248 $ 159,477 Other current assets: Notes receivable $ 12,127 $ 13,033 Income tax and other tax receivable 15,041 10,681 Billable tooling 15,267 3,778 Short-term derivative financial instruments 6,564 300 Prepaid expenses 6,239 3,407 Receivables due from factor 5,490 — Other 3,869 1,576 Total other current assets $ 64,597 $ 32,775 Property and equipment: Machinery and equipment $ 214,342 $ 155,463 Buildings and improvements 123,714 100,788 Information technology 39,726 33,060 Production tooling 24,839 25,180 Leasehold improvements 12,271 11,445 Construction in progress 29,023 14,506 Total property and equipment 443,915 340,442 Less: accumulated depreciation ( 199,435 ) ( 185,172 ) Total property and equipment, net $ 244,480 $ 155,270 Other current liabilities: Accrued employee liabilities $ 32,031 $ 28,818 Liabilities from discounts and rebates 26,640 27,343 Income tax and other taxes payable 14,459 17,068 Restructuring 588 1,494 Accrued warranty 2,380 1,916 Other 17,716 5,554 Total other current liabilities $ 93,814 $ 82,193

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment	Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2022 and 2021 were as follows: Automotive Medical Total Balance as of December 31, 2020 $ 39,495 $ 28,529 $ 68,024 Acquisition of B&E — 976 976 Exchange rate impact ( 2,166 ) ( 801 ) ( 2,967 ) Balance as of December 31, 2021 $ 37,329 $ 28,704 $ 66,033 Acquisition of Dacheng — 19,016 19,016 Acquisition of Alfmeier 34,494 — 34,494 Exchange rate impact 1,246 ( 1,015 ) 231 Balance as of December 31, 2022 $ 73,069 $ 46,705 $ 119,774
Summary of Other Intangible Assets and Accumulated Amortization Balances	Other intangible assets and accumulated amortization balances as of December 31, 2022 and 2021 were as follows: Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 112,286 $ ( 65,748 ) $ 46,538 Technology 44,745 ( 25,709 ) 19,036 Product development costs 18,774 ( 18,456 ) 318 Software development 1,007 — 1,007 Indefinite-lived: Tradenames 7,034 — 7,034 Balance as of December 31, 2022 $ 183,846 $ ( 109,913 ) $ 73,933 Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 90,448 $ ( 64,105 ) $ 26,343 Technology 29,464 ( 24,487 ) 4,977 Product development costs 20,329 ( 19,772 ) 557 Software development 1,007 — 1,007 Indefinite-lived: Tradenames 4,670 — 4,670 Balance as of December 31, 2021 $ 145,918 $ ( 108,364 ) $ 37,554
Summary of Estimate of Other Intangible Asset Amortization	An estimate of other intangible asset amortization by year, is as follows: 2023 $ 8,294 2024 $ 7,297 2025 $ 7,284 2026 $ 7,284 2027 $ 7,284

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Components of Lease Expense and Other Information	Components of lease expense for the years ended December 31, 2022, 2021 and 2020 were as follows: Year Ended December 31, 2022 2021 2020 Lease cost: Operating lease cost $ 8,040 $ 8,227 $ 6,773 Amortization of ROU assets - finance leases 168 — — Interest on lease liabilities - finance leases 16 — — Short-term lease cost 1,773 1,941 1,834 Sublease income ( 101 ) ( 163 ) ( 158 ) Total lease cost $ 9,896 $ 10,005 $ 8,449 Other information related to leases is as follows: Year Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 10,381 $ 7,685 Operating cash flows for finance leases 16 — Financing cash flows for finance leases 164 — Right-of-use lease assets obtained in exchange for lease obligations: Operating leases $ 15,902 $ 2,379 Finance leases 1,180 — December 31, 2022 December 31, 2021 Weighted average remaining lease term: Operating leases 5.7 years 6.9 years Finance leases 2.7 years N/A Weighted average discount rate: Operating leases 4.35 % 4.53 % Finance leases 3.57 % N/A
Summary of Operating Leases Under all Non-Cancellable Operating Leases	A summary of operating leases as of December 31, 2022, under all non-cancellable operating leases with terms exceeding one year is as follows: 2023 $ 8,074 2024 7,003 2025 4,984 2026 3,122 2027 1,631 2028 or later 6,538 Total future minimum lease payments 31,352 Less imputed interest ( 3,671 ) Total $ 27,681
Summary of Finance Leases Under all Non-Cancellable Finance Leases	A summary of finance leases as of December 31, 2022, under all non-cancellable finance leases with terms exceeding one year is as follows: 2023 $ 432 2024 437 2025 148 2026 68 Total future minimum lease payments $ 1,085

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Summary of Company's Debt	The following table summarizes the Company’s debt as of December 31, 2022 and 2021: December 31, 2022 2021 Interest Principal Interest Principal Credit Agreement: U.S. Revolving Note (U.S. Dollar denominations) 5.80 % $ 232,000 1.35 % $ 35,000 Other loans 3.89 % - 5.21 % 2,011 5.21 % 3,750 Finance leases N/A 1,085 N/A — Total debt 235,096 38,750 Current maturities ( 2,443 ) ( 2,500 ) Long-term debt, less current maturities $ 232,653 $ 36,250
Principal Maturities of Debt	The scheduled principal maturities of our debt as of December 31, 2022 were as follows: U.S. Other Debt Total 2023 $ — $ 2,443 $ 2,443 2024 — 437 437 2025 — 148 148 2026 — 68 68 2027 232,000 — 232,000 Total $ 232,000 $ 3,096 $ 235,096

Pension and Other Post Retire_2

Pension and Other Post Retirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost for Company's Defined Benefit Plans	The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2022, 2021 and 2020 were as follows: U.S. Plan German Plan Year Ended December 31, Year Ended December 31, 2022 2021 2020 2022 2021 2020 Net periodic benefit cost: Service cost $ — $ — $ — $ — $ — $ — Interest cost 56 42 85 92 91 88 Expected return on plan assets — — — ( 109 ) ( 120 ) ( 121 ) Amortization of prior service cost and actuarial loss 22 26 7 114 133 124 Net periodic benefit cost $ 78 $ 68 $ 92 $ 97 $ 104 $ 91 Assumptions: Discount rate 1.80 % 1.20 % 2.40 % 1.25 % 1.08 % 1.06 % Long-term return on assets N/A N/A N/A 2.90 % 2.90 % 3.10 %
Reconciliation of Change in Benefit Obligation, Change in Plan Assets and Balance Sheet Classification	A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2022 and 2021 is as follows: U.S. Plan German Plan As of December 31, As of December 31, 2022 2021 2022 2021 Change in projected benefit obligation: Balance at beginning of year $ 3,446 $ 3,847 $ 8,102 $ 8,934 Interest cost 56 42 92 91 Paid pension distributions ( 342 ) ( 342 ) ( 281 ) ( 310 ) Actuarial (gain) loss ( 349 ) ( 101 ) ( 2,001 ) 9 Exchange rate impact — — ( 514 ) ( 622 ) Balance at end of year $ 2,811 $ 3,446 $ 5,398 $ 8,102 Change in plan assets: Balance at beginning of year — — 4,069 4,276 Actual return on plan assets — — 89 98 Contributions — — — 310 Paid pension distributions — — — ( 310 ) Exchange rate impact — — ( 240 ) ( 305 ) Balance at end of year $ — $ — $ 3,918 $ 4,069 Underfunded Status $ ( 2,811 ) $ ( 3,446 ) $ ( 1,480 ) $ ( 4,033 ) Balance sheet classification: Other current liabilities $ ( 342 ) $ ( 342 ) $ ( 314 ) $ ( 306 ) Pension benefit obligation ( 2,469 ) ( 3,104 ) ( 1,166 ) ( 3,727 ) Accumulated other comprehensive loss (pre-tax): Actuarial losses 205 575 965 3,288 Assumptions: Discount rate 4.65 % 1.80 % 4.10 % 1.25 %
Summary of Pre-tax Amounts in AOCI Expected to Be Recognized in Net Periodic Benefit Cost	Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2023 are as follows: U.S Plan German Plan Actuarial losses $ - $ 22
Summary of Accumulated Benefit Obligations	The accumulated benefit obligations were as follows: U.S. Plan German Plan As of December 31, As of December 31, 2022 2021 2022 2021 Accumulated benefit obligation $ 2,811 $ 3,446 $ 5,398 $ 8,102
Schedule of Future Expected Pension Payments	The schedule of future expected pension payments is as follows: Projected Pension Year U.S Plan German Plan 2023 $ 342 $ 311 2024 342 303 2025 342 294 2026 342 285 2027 342 274 2028-2031 1,710 2,732 Total $ 3,420 $ 4,199

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Reconciliation of Changes in Accrued Warranty Costs	The following is a reconciliation of the changes in accrued warranty costs: Year Ended December 31, 2022 2021 Balance at beginning of year $ 1,916 $ 2,391 Warranty opening balance from acquired entities 907 - Warranty claims paid ( 1,841 ) ( 2,164 ) Warranty expense for products shipped during the current period 1,584 1,813 Adjustments to warranty estimates from prior periods ( 274 ) ( 73 ) Adjustments due to currency translation 88 ( 51 ) Balance at end of year $ 2,380 $ 1,916

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings per Share and Weighted Average Shares Outstanding Used in Calculating Basic and Diluted Earnings per Share	The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Year Ended December 31, 2022 2021 2020 Net income $ 24,441 $ 93,434 $ 59,690 Basic weighted average shares of Common Stock outstanding 33,126,202 33,085,732 32,666,025 Dilutive effect of stock options, restricted stock awards and restricted stock units 376,952 423,988 362,079 Diluted weighted average shares of Common Stock outstanding 33,503,154 33,509,720 33,028,104 Basic earnings per share $ 0.74 $ 2.82 $ 1.83 Diluted earnings per share $ 0.73 $ 2.79 $ 1.81
Common Stock Issuable upon Exercise of Certain Stock Options	The following table represents Common Stock issuable upon the exercise of certain stock options that have been excluded from the diluted earnings calculation because the effect of their inclusion would be anti-dilutive. Year Ended December 31, 2022 2021 2020 Anti-dilutive securities share impact — — 12,000

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Information Related to Recurring Fair Value Measurement of Derivative Financial Instruments in the Consolidated Balance Sheet	Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2022 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 40,063 Other current assets $ 3,791 Other current liabilities $ — $ 3,791 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,772 Other current liabilities $ — $ 2,772 Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2021 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 13,974 Other current assets $ 294 Other current liabilities $ — $ 294 Commodity hedges Level 2 $ 309 Other current assets $ 6 Other current liabilities $ — $ 6
Information Related to Effect of Derivative Instruments in the Consolidated Statements of Income	Information related to the effect of derivative instruments in the consolidated statements of income is as follows: Year Ended December 31, Location 2022 2021 2020 Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Cost of sales – income $ 1,458 $ 1,609 $ ( 1,629 ) Other comprehensive (loss) income 3,496 ( 1,217 ) 272 Foreign currency loss — — ( 118 ) Total foreign currency derivatives $ 4,954 $ 392 $ ( 1,475 ) Commodity derivatives Cost of sales – income $ 19 $ 14 $ — Other comprehensive (loss) income ( 6 ) 6 — Total commodity derivatives $ 13 $ 20 $ — Derivatives Not Designated as Hedging Instruments Foreign currency derivatives Foreign currency (loss) gain $ ( 3,806 ) $ - $ - Total foreign currency derivatives $ ( 3,806 ) $ - $ - Interest rate contracts Interest income (expense), net $ 2,772 $ - $ - Total interest rate derivatives $ 2,772 $ - $ -

Reclassifications Out of Accu_2

Reclassifications Out of Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Income (Loss)	Reclassification adjustments and other activities impacting accumulated other comprehensive income (loss) during the years ended December 31, 2022, 2021 and 2020 are as follows: Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 5 $ 154 $ ( 36,922 ) Other comprehensive income (loss) before reclassifications 2,341 ( 13,786 ) 13 4,954 ( 6,478 ) Income tax effect of other comprehensive income (loss) before reclassifications ( 621 ) ( 295 ) ( 3 ) ( 1,092 ) ( 2,011 ) Amounts reclassified from accumulated other comprehensive loss into net income 137 — ( 19 ) a ( 1,458 ) a ( 1,340 ) Income taxes reclassified into net income ( 31 ) — 4 289 262 Net current period other comprehensive income (loss) 1,826 ( 14,081 ) ( 5 ) 2,693 ( 9,567 ) Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ — $ 2,847 $ ( 46,489 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2020 $ ( 3,451 ) $ ( 12,637 ) $ — $ 1,106 $ ( 14,982 ) Other comprehensive income (loss) before reclassifications 512 ( 21,274 ) 20 392 ( 20,350 ) Income tax effect of other comprehensive income (loss) before reclassifications ( 71 ) ( 277 ) ( 4 ) ( 85 ) ( 437 ) Amounts reclassified from accumulated other comprehensive loss into net income 159 — ( 14 ) a ( 1,609 ) a ( 1,464 ) Income taxes reclassified into net income ( 42 ) — 3 350 311 Net current period other comprehensive income (loss) 558 ( 21,551 ) 5 ( 952 ) ( 21,940 ) Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 5 $ 154 $ ( 36,922 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. Defined Benefit Foreign Currency Commodity Hedge Derivatives Foreign Currency Total Balance at December 31, 2019 $ ( 3,371 ) $ ( 39,879 ) $ — $ 895 $ ( 42,355 ) Other comprehensive (loss) income before reclassifications ( 328 ) 27,147 — ( 1,751 ) 25,068 Income tax effect of other comprehensive (loss) income before reclassifications 117 95 — 381 593 Amounts reclassified from accumulated other comprehensive loss into net income $ 131 — — 2,023 a 2,154 Income taxes reclassified into net income — — — ( 442 ) ( 442 ) Net current period other comprehensive (loss) income ( 80 ) 27,242 — 211 27,373 Balance at December 31, 2020 $ ( 3,451 ) $ ( 12,637 ) $ — $ 1,106 $ ( 14,982 ) (a) The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income.

Accounting for Stock Based Co_2

Accounting for Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Recognized and Unrecognized Stock-based Compensation Expense	The total recognized and unrecognized stock-based compensation expense is as follows: Stock-Based Compensation Expense 2022 2021 2020 Unrecognized Stock-Based Compensation Expense at December 31, 2022 Remaining Weighted Average Vesting Period RSUs $ 5,551 $ 4,594 $ 3,137 $ 8,724 1.80 PSUs 954 5,535 3,361 6,745 1.97 Restricted Shares 888 1,198 1,495 419 0.42 SARs ( 794 ) 2,721 5,494 - - Stock options - 482 836 - - Total Stock-Based Compensation $ 6,599 $ 14,530 $ 14,323 $ 15,888 1.84
Summary of Performance Stock Unit Activity	The following table summarizes performance stock unit activity during the years ended December 31, 2022, 2021 and 2020: Unvested Performance Stock Units Relative TSR Target Weighted-Average ROIC Target Weighted-Average Adjusted EBITDA Target Shares Weighted-Average Total Outstanding at December 31, 2019 95,041 $ 61.77 95,039 $ 42.78 — $ — 190,080 Granted 77,967 49.25 77,967 33.72 — — 155,934 Vested — — — — — — — Forfeited ( 15,090 ) 56.84 ( 15,090 ) 39.96 — — ( 30,180 ) Outstanding at December 31, 2020 157,918 $ 56.06 157,916 $ 38.58 — $ — 315,834 Granted 20,626 118.08 40,580 78.98 39,930 79.49 101,136 Performance Adjustment 30,828 69.18 ( 30,830 ) 44.92 — — ( 2 ) Vested ( 61,656 ) 69.18 — — — — ( 61,656 ) Forfeited ( 16,148 ) 61.10 ( 17,374 ) 44.32 ( 2,454 ) 79.49 ( 35,976 ) Outstanding at December 31, 2021 131,568 $ 62.09 150,292 $ 47.52 37,476 $ 79.49 319,336 Granted 21,324 103.31 42,640 68.63 42,640 68.63 106,604 Performance Adjustment 45,004 57.46 ( 2,258 ) 41.61 — — 42,746 Vested ( 90,371 ) 57.46 ( 43,106 ) 41.61 — — ( 133,477 ) Forfeited ( 4,724 ) 68.67 ( 6,493 ) 56.87 ( 3,543 ) 75.10 ( 14,760 ) Outstanding at December 31, 2022 102,801 $ 65.20 141,075 $ 55.18 76,573 $ 73.66 320,449
Restricted Stock Activity	The following table summarizes restricted stock activity during the years ended December 31, 2022, 2021 and 2020: Unvested Restricted Shares Shares Weighted-Average Outstanding at December 31, 2019 34,920 $ 38.31 Granted 32,406 39.96 Vested ( 32,420 ) 38.33 Forfeited — — Outstanding at December 31, 2020 34,906 $ 39.82 Granted 13,742 70.18 Vested ( 37,272 ) 41.70 Forfeited — — Outstanding at December 31, 2021 11,376 $ 70.33 Granted 13,600 73.54 Vested ( 11,376 ) 70.33 Forfeited — — Outstanding at December 31, 2022 13,600 $ 73.54
SARs Activity	The following table summarizes SARs activity during the years ended December 31, 2022, 2021 and 2020: Stock Appreciation Rights Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2019 554,250 $ 39.41 2.84 $ 2,981 Granted — — Exercised ( 342,150 ) 38.22 Forfeited ( 40,500 ) 44.39 Outstanding at December 31, 2020 171,600 $ 40.60 2.44 $ 4,224 Granted — — Exercised ( 116,000 ) 40.34 Forfeited — — Outstanding at December 31, 2021 55,600 $ 41.15 1.28 $ 2,544 Granted — — Exercised ( 40,850 ) 42.27 Forfeited — — Outstanding at December 31, 2022 14,750 $ 38.05 1.15 $ 402 Exercisable at December 31, 2022 14,750 $ 38.05 1.15 $ 402
Summary of Stock Option Activity	The following table summarizes stock option activity during the years ended December 31, 2022, 2021 and 2020: Options Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2019 869,000 $ 37.87 3.51 $ 5,172 Granted — — Exercised ( 434,250 ) 38.12 Forfeited ( 6,750 ) 38.05 Outstanding at December 31, 2020 428,000 $ 37.61 3.20 $ 11,815 Granted — — Exercised ( 215,250 ) 38.46 Forfeited ( 6,000 ) 38.05 Outstanding at December 31, 2021 206,750 $ 36.72 2.60 $ 10,375 Granted — — Exercised ( 44,116 ) 37.87 Forfeited - - Outstanding at December 31, 2022 162,634 $ 36.41 2.68 $ 8,212 Exercisable at December 31, 2022 162,634 $ 36.41 2.68 $ 8,212
RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted Stock Activity	The following table summarizes restricted stock unit activity during the years ended December 31, 2022, 2021 and 2020: Unvested Restricted Stock Units Time Vesting Weighted-Average Outstanding at December 31, 2019 141,741 $ 42.16 Granted 132,864 34.41 Vested ( 50,953 ) 42.13 Forfeited ( 14,747 ) 39.16 Outstanding at December 31, 2020 208,905 $ 37.26 Granted 93,539 79.79 Vested ( 88,296 ) 38.49 Forfeited ( 20,522 ) 48.76 Outstanding at December 31, 2021 193,626 $ 56.02 Granted 117,507 66.86 Vested ( 95,692 ) 49.85 Forfeited ( 13,863 ) 70.52 Outstanding at December 31, 2022 201,578 $ 64.27

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Earnings Before Income Taxes	The income tax provisions were calculated based upon the following components of earnings before income tax for the years ended December 31, 2022, 2021 and 2020: Year Ended December 31, 2022 2021 2020 Earnings before income tax: Domestic $ ( 34,211 ) $ ( 4,547 ) $ ( 11,374 ) Foreign 72,593 118,399 92,930 Earnings before income tax $ 38,382 $ 113,852 $ 81,556
Provision for Income Taxes	The components of the provision for income taxes for the years ended December 31, 2022, 2021 and 2020 are summarized as follows: Year Ended December 31, 2022 2021 2020 Current income tax expense: Federal $ 3,006 $ 1,944 $ 784 State and local 650 234 83 Foreign 17,607 18,390 20,150 Total current income tax expense $ 21,263 20,568 21,017 Deferred income tax (benefit) expense: Federal ( 5,971 ) ( 4,400 ) ( 2,302 ) State and local ( 213 ) ( 91 ) 32 Foreign ( 1,138 ) 4,341 3,119 Total deferred (benefit) income tax expense ( 7,322 ) ( 150 ) 849 Total income tax expense $ 13,941 $ 20,418 $ 21,866
Deferred Tax Assets and Deferred Tax Liabilities	The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2022 and 2021: December 31, 2022 2021 Deferred tax assets: Net operating losses $ 43,296 $ 25,610 Intangible assets 4,417 21,179 Research and development credits 7,835 9,736 Property and equipment 6,983 7,071 Valuation reserves and accrued liabilities 8,388 7,333 Capitalized Research and Development Costs 19,087 9,018 Stock compensation 3,051 3,832 Defined benefit obligation 1,265 1,466 Inventory 6,762 1,914 Other credits 10,296 10,158 Other 790 146 Total deferred tax asset 112,170 97,463 Valuation allowance ( 36,671 ) ( 16,090 ) Deferred tax liabilities: Unrealized foreign currency exchange gains $ ( 2,413 ) $ ( 2,488 ) Undistributed profits of subsidiary ( 5,981 ) ( 6,676 ) Property and equipment ( 15,423 ) ( 2,420 ) Other ( 3,056 ) ( 1,428 ) Total deferred tax liability ( 26,873 ) ( 13,012 ) Net deferred tax asset $ 48,626 $ 68,361
Reconciliations Between Statutory Federal Income Tax Rate and Effective Rate	Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2022, 2021 and 2020 are as follows: Year Ended December 31, 2022 2021 2020 Statutory Federal income tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) resulting from: Change in valuation allowance 6.4 % ( 1.2 )% ( 0.4 )% Effect of different tax rates of foreign jurisdictions ( 4.9 )% ( 5.2 )% ( 4.7 )% Tax credits & deductions related to R&D ( 10.1 )% ( 2.3 )% ( 3.8 )% Non-deductible expenses 14.9 % 1.7 % 2.1 % Non-deductible expenses related to acquisitions 7.0 % 0.0 % 0.0 % Other foreign, state and local taxes 0.7 % 1.6 % 1.4 % Tax impact of foreign income 4.2 % 3.6 % 4.9 % Stock option compensation ( 3.8 )% ( 2.0 )% ( 0.4 )% Other 0.9 % 0.7 % 6.7 % Effective rate 36.3 % 17.9 % 26.8 %
Net Operating Loss Carryforwards	The Company has Net Operating Loss (“NOL”) carryforwards as follows: Jurisdiction Amount as of December 31, 2022 Years of Expiration U.S. state income tax $ 54,912 2023 - 2042 Foreign $ 320,417 Indefinite
Reconciliation of Unrecognized Tax Benefits	The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, 2022 2021 2020 Balance at beginning of year $ 5,665 $ 4,967 $ 3,795 Additions based on tax position related to current year 972 1,105 1,489 Additions based on tax position related to prior year 433 160 179 Reductions from settlements and statute of limitation expiration ( 610 ) ( 312 ) $ ( 650 ) Effect of foreign currency translation ( 275 ) ( 255 ) 154 Balance at end of year $ 6,185 $ 5,665 $ 4,967

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss)	The tables below present segment information about the reported product revenues and operating income of the Company for years ended December 31, 2022, 2021 and 2020. With the exception of goodwill, asset information by segment is not reported since the Company does not manage assets at a segment level. Automotive Medical Corporate Total 2022: Product revenues $ 1,161,616 $ 43,040 $ — $ 1,204,656 Depreciation and amortization 39,815 3,344 1,235 44,394 Operating income (loss) 118,433 ( 4,029 ) ( 66,097 ) 48,307 2021: Product revenues $ 1,004,633 $ 41,517 $ — $ 1,046,150 Depreciation and amortization 35,389 2,460 931 38,780 Operating income (loss) 162,994 ( 1,829 ) ( 46,159 ) 115,006 2020: Product revenues $ 869,998 $ 43,100 $ — $ 913,098 Depreciation and amortization 37,662 2,366 1,086 41,114 Operating income (loss) 138,410 971 ( 50,164 ) 89,217
Segment Information About Reported Segment Product Revenues by Product Category	Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2022, 2021 and 2020 are as follows: Year Ended December 31, 2022 2021 2020 Climate Control Seat $ 426,046 $ 393,816 $ 342,550 Seat Heaters 283,970 270,054 249,665 Steering Wheel Heaters 120,949 102,496 76,272 Automotive Cables 76,962 84,114 73,997 Battery Performance Solutions 71,907 69,594 50,901 Electronics 44,106 51,648 53,238 Lumbar and Massage Comfort Solutions (a) 56,980 — — Valve System Technologies (a) 41,980 — — Other Automotive 38,716 32,911 23,375 Subtotal Automotive segment 1,161,616 1,004,633 869,998 Medical segment (a) 43,040 41,517 43,100 Total Company $ 1,204,656 $ 1,046,150 $ 913,098 (a) Includes product revenues from acquisitions since their respective acquisition dates (see Note 4).
Product Revenues Information by Geographic Area	Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2022, 2021 and 2020 is as follows: Year Ended December 31, 2022 2021 2020 United States $ 472,468 $ 404,466 $ 377,577 China 183,419 142,816 101,039 South Korea 94,937 93,516 88,745 Germany 75,367 66,929 58,536 Japan 57,718 63,527 57,785 Czech Republic 49,293 43,931 37,542 Romania 47,532 51,367 33,147 Slovakia 34,686 30,004 21,568 Finland 33,627 29,325 15,958 Mexico 23,233 18,194 13,429 Other 132,376 102,075 107,772 Total Non-U.S. 732,188 641,684 535,521 Total Company $ 1,204,656 $ 1,046,150 $ 913,098
Percentage of Total Product Revenues Generated from Customers	The table below lists the percentage of total product revenues generated from sales to customers which contributed 10% or more to the Company’s total consolidated product revenue for the years ended December 31, 2022, 2021 and 2020: Year Ended December 31, 2022 2021 2020 Lear 16 % 15 % 15 % Adient 15 % 15 % 14 %
Schedule of Property and Equipment, Net by Geographic Area	Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2022 and 2021 is as follows: December 31, Property and equipment, net 2022 2021 Germany $ 47,342 $ 16,174 China 43,162 25,411 United States 41,034 19,222 Mexico 31,597 20,296 North Macedonia 27,808 32,682 Vietnam 19,808 19,876 Czech Republic 11,381 — Hungary 11,736 8,995 Ukraine 5,077 9,539 Other 5,535 3,075 Total $ 244,480 $ 155,270

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) Segment	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Basis Of Presentation And Accounting Policies [Line Items]
Number of reportable segments | Segment	2
capitalized costs to obtain contract	$ 2,239	$ 1,946
Amortization of capitalized costs into product revenues	78	174
Cash and cash equivalents	153,891	190,606
Allowance for doubtful accounts	1,220	1,399	$ 1,161	$ 1,193
Depreciation expense	$ 33,730	29,622	$ 31,037
Investment amount		5,200
Operating lease, description	The Company has operating leases for office, manufacturing and research and development facilities, as well as land leases for certain manufacturing facilities that are accounted for as operating leases. We also have operating leases for office equipment and automobiles.
Operating lease, existence of option to extend	true
Operating lease, options to extend	Excluding land leases, our leases have remaining lease terms ranging from less than 1 year to 9 years and may include options to extend the lease.
Forciot Oy | Gentherm Automotive Segment
Basis Of Presentation And Accounting Policies [Line Items]
Investment amount		2,357
Autotech Fund III, L.P.
Basis Of Presentation And Accounting Policies [Line Items]
Investment commitment	$ 495	5,000
Capital contribution description	As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten-year life of the fund.
Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Reimbursable tooling capitalized within prepaid expenses and other current assets	$ 15,267	$ 3,778
Concentration of Credit Risk | Accounts receivable | Lear
Basis Of Presentation And Accounting Policies [Line Items]
Concentration risk percentage	17%	18%
Concentration of Credit Risk | Accounts receivable | Adient
Basis Of Presentation And Accounting Policies [Line Items]
Concentration risk percentage	18%	22%
Foreign Jurisdictions
Basis Of Presentation And Accounting Policies [Line Items]
Cash and cash equivalents	$ 108,620	$ 161,496
Minimum
Basis Of Presentation And Accounting Policies [Line Items]
Expected period of costs to be realized to recognize assets	1 year
Operating lease, term of contract	1 year
Minimum | Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Property plant and equipment, estimated useful life	2 years
Minimum | Ground
Basis Of Presentation And Accounting Policies [Line Items]
Operating lease, term of contract	3 years
Maximum
Basis Of Presentation And Accounting Policies [Line Items]
Original maturities of highly liquid investments	90 days
Operating lease, term of contract	9 years
Maximum | Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Property plant and equipment, estimated useful life	10 years
Maximum | Ground
Basis Of Presentation And Accounting Policies [Line Items]
Operating lease, term of contract	40 years
Entities Ownership Interest
Basis Of Presentation And Accounting Policies [Line Items]
Ownership interest	20%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Balance at beginning of year	$ 1,399	$ 1,161	$ 1,193
Charged to costs and expenses	1,088	1,066	1,298
Other activity		(12)	33
Deductions from reserves	(1,267)	(816)	(1,363)
Balance at end of year	$ 1,220	$ 1,399	$ 1,161

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2022
Plant and Equipment
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	10 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	Term of lease
Minimum | Buildings and Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	1 year
Minimum | Production Tooling
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	2 years
Minimum | Information Technology
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	1 year
Maximum | Buildings and Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	30 years
Maximum | Production Tooling
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	10 years
Maximum | Information Technology
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	5 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Fair Value and Corresponding Useful Lives for Acquired Intangibles Assets (Detail)	12 Months Ended
	Dec. 31, 2022
Customer Related | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	8 years
Customer Related | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	15 years
Technology | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	5 years
Technology | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	12 years
Software Development Costs | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	4 years
Software Development Costs | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	5 years
Product Development Costs | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	5 years
Product Development Costs | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	10 years

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands				12 Months Ended
	Aug. 01, 2022	Jul. 13, 2022	Jul. 01, 2021	Dec. 31, 2022
Beckmann & Egle Industrieelektronik GmbH
Business Acquisition [Line Items]
Medical business segment unit amount acquired			$ 2,827
Alfmeier
Business Acquisition [Line Items]
Acquisition date	Aug. 01, 2022
Percentage of equity interests acquired	100%
Total consideration	$ 170,700
Cash payments	170,439			$ 170,439
Contingent payments	$ 261			$ 261
Dacheng
Business Acquisition [Line Items]
Acquisition date		Jul. 13, 2022
Percentage of equity interests acquired		100%
Total consideration		$ 35,048
Contingent payments		$ 3,000

Acquisitions - Summary of Produ

Acquisitions - Summary of Product Revenues and Operating Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Product revenues	$ 1,204,656	$ 1,046,150	$ 913,098
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Operating income	$ 48,307	$ 115,006	$ 89,217
Alfmeier
Business Acquisition [Line Items]
Product revenues	$ 98,960
Type of Revenue [Extensible List]	us-gaap:ProductMember
Net loss	$ (2,675)
Dacheng
Business Acquisition [Line Items]
Product revenues	$ 3,499
Type of Revenue [Extensible List]	us-gaap:ProductMember
Net loss	$ (217)

Acquisitions - Summary of Purch

Acquisitions - Summary of Purchase Consideration to Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands				12 Months Ended
	Dec. 31, 2022	Aug. 01, 2022	Jul. 13, 2022	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired				$ 205,487	$ 2,827
Goodwill	$ 119,774			119,774	$ 66,033
Alfmeier
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired	170,700
Accounts receivable	24,867			24,867
Inventory	35,920			35,920
Prepaid expenses and other assets		$ 20,846
Operating lease right-of-use assets	4,608			4,608
Property and equipment	91,184			91,184
Other intangible assets	31,459	31,459		31,459
Goodwill	34,494			34,494
Assumed liabilities	(55,019)			(55,019)
Deferred tax liabilities	(17,659)			(17,659)
Net assets acquired	170,700			170,700
Alfmeier | Initial Allocation
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired		164,887
Accounts receivable		24,988
Inventory		36,026
Prepaid expenses and other assets		20,920
Operating lease right-of-use assets		4,608
Property and equipment		89,942
Other intangible assets		22,668
Goodwill		43,678
Assumed liabilities		(55,994)
Deferred tax liabilities		(21,949)
Net assets acquired		164,887
Alfmeier | Measurement Period Adjustments
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired		5,813
Accounts receivable		(121)
Inventory		(106)
Prepaid expenses and other assets		(74)
Property and equipment		1,242
Other intangible assets		8,791
Goodwill		(9,184)
Assumed liabilities		(975)
Deferred tax liabilities		(4,290)
Net assets acquired		$ 5,813
Dacheng
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired	35,048
Accounts receivable	662			662
Inventory	1,765			1,765
Prepaid expenses and other assets	174			174
Operating lease right-of-use assets	841			841
Property and equipment	684			684
Other intangible assets	20,059		$ 20,059	20,059
Goodwill	19,016			19,016
Assumed liabilities	(2,839)			(2,839)
Deferred tax liabilities	(5,314)			(5,314)
Net assets acquired	$ 35,048			$ 35,048
Dacheng | Initial Allocation
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired			35,048
Accounts receivable			746
Inventory			1,942
Prepaid expenses and other assets			152
Operating lease right-of-use assets			841
Property and equipment			684
Other intangible assets			19,094
Goodwill			22,995
Assumed liabilities			(2,799)
Deferred tax liabilities			(8,607)
Net assets acquired			35,048
Dacheng | Measurement Period Adjustments
Business Acquisition [Line Items]
Accounts receivable			(84)
Inventory			(177)
Prepaid expenses and other assets			22
Other intangible assets			965
Goodwill			(3,979)
Assumed liabilities			40
Deferred tax liabilities			$ (3,293)

Acquisitions - Summary of Pur_2

Acquisitions - Summary of Purchase Consideration to Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) - Alfmeier - USD ($) $ in Thousands		12 Months Ended
	Aug. 01, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Cash payments	$ 170,439	$ 170,439
Contingent payments	$ 261	$ 261

Acquisitions - Summary of Alloc

Acquisitions - Summary of Allocation of Purchase Consideration to Other Intangible Assets Acquired (Detail) - USD ($) $ in Thousands			12 Months Ended
	Aug. 01, 2022	Jul. 13, 2022	Dec. 31, 2022
Alfmeier
Business Acquisition [Line Items]
Preliminary Fair Value, Total	$ 31,459		$ 31,459
Alfmeier | Customer Related
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived	$ 19,812
Weighted Average Life (in years)	14 years		14 years
Alfmeier | Technology
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived	$ 11,647
Weighted Average Life (in years)	9 years		9 years
Dacheng
Business Acquisition [Line Items]
Preliminary Fair Value, Total		$ 20,059	$ 20,059
Dacheng | Tradenames
Business Acquisition [Line Items]
Preliminary Fair Value, Indefinite-lived		2,473
Dacheng | Customer Related
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived		$ 12,837
Weighted Average Life (in years)		12 years	12 years
Dacheng | Technology
Business Acquisition [Line Items]
Preliminary Fair Value, Definite-lived		$ 4,749
Weighted Average Life (in years)		12 years	12 years

Acquisitions - Summary of Unaud

Acquisitions - Summary of Unaudited Pro Forma Information (Detail) - Alfmeier - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Product revenues	$ 1,348,295	$ 1,304,505
Net Income	$ 17,645	$ 92,079

Restructuring and Impairments -

Restructuring and Impairments - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 637	$ 3,857	$ 5,803
Non-cash impairment charges	$ 6,291
Description and timing of disposal	The Company is evaluating a potential sale of the non-automotive electronics business or substantially all of its assets. If such sale is not pursued or is unsuccessful, the Company intends to wind-down the operations of the business over approximately eight to twelve months, subject to discussions with customers and suppliers.
Property and Equipment
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges	$ 690
Intangible Assets
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges	5,601
Inventory
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges	9,378
Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	10,359
Restructuring reserve accelerated depreciation	198	1,665	1,019
Restructuring expenses remains accrued	588
Employee Separation Costs | Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	56	1,303	(832)
Employee Separation Costs | Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	0	889	5,382
Other Restructuring | Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 383	$ 0	$ 234

Restructuring and Impairments_2

Restructuring and Impairments - Summary of Restructuring Expense by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 637	$ 3,857	$ 5,803
Operating Segments | Automotive Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 637	2,793	5,075
Operating Segments | Medical Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			112
Operating Segments | Corporate Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses		$ 1,064	$ 616

Restructuring and Impairments_3

Restructuring and Impairments - Summary of Restructuring Activity for All Restructuring Initiatives (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period	$ 1,494	$ 5,627
Additions, charged to restructuring expenses	587	4,333
Change in estimate	50	(476)
Cash payments	(1,462)	(7,838)
Non-cash utilization		(218)
Currency translation and other	(81)	66
Balance, end of period	588	1,494
Employee Separation Costs
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period	1,494	5,627
Additions, charged to restructuring expenses	6	2,406
Change in estimate	50	(214)
Cash payments	(881)	(6,129)
Currency translation and other	(81)	(196)
Balance, end of period	588	1,494
Other Restructuring
Restructuring Cost And Reserve [Line Items]
Additions, charged to restructuring expenses	581	1,927
Change in estimate		(262)
Cash payments	$ (581)	(1,709)
Non-cash utilization		(218)
Currency translation and other		$ 262

Details of Certain Financial _3

Details of Certain Financial Statement Components (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Inventory:
Raw materials, net of reserve	$ 136,217	$ 96,426
Work in process, net of reserve	17,695	9,495
Finished goods, net of reserve	64,336	53,556
Total inventory, net	218,248	159,477
Other current assets:
Notes receivable	12,127	13,033
Income tax and other tax receivable	15,041	10,681
Billable tooling	15,267	3,778
Short-term derivative financial instruments	6,564	300
Prepaid expenses	6,239	3,407
Receivables due from factor	5,490
Other	3,869	1,576
Total other current assets	64,597	32,775
Property and equipment:
Machinery and equipment	214,342	155,463
Buildings and improvements	123,714	100,788
Information technology	39,726	33,060
Production tooling	24,839	25,180
Leasehold improvements	12,271	11,445
Construction in progress	29,023	14,506
Total property and equipment	443,915	340,442
Less: accumulated depreciation	(199,435)	(185,172)
Total property and equipment, net	244,480	155,270
Other current liabilities:
Accrued employee liabilities	32,031	28,818
Liabilities from discounts and rebates	26,640	27,343
Income tax and other taxes payable	14,459	17,068
Restructuring	588	1,494
Accrued warranty	2,380	1,916	$ 2,391
Other	17,716	5,554
Total other current liabilities	$ 93,814	$ 82,193

Goodwill and Other Intangible_2

Goodwill and Other Intangibles - Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill [Line Items]
Balance, beginning of period	$ 66,033
Balance, end of period	119,774	$ 66,033
Operating Segments
Goodwill [Line Items]
Balance, beginning of period	66,033	68,024
Acquisition		976
Exchange rate impact	231	(2,967)
Balance, end of period	119,774	66,033
Automotive Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period	37,329	39,495
Exchange rate impact	1,246	(2,166)
Balance, end of period	73,069	37,329
Medical Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period	28,704	28,529
Acquisition		976
Exchange rate impact	(1,015)	(801)
Balance, end of period	46,705	$ 28,704
Dacheng [Member]
Goodwill [Line Items]
Balance, end of period	19,016
Dacheng [Member] | Operating Segments
Goodwill [Line Items]
Acquisition	19,016
Dacheng [Member] | Medical Segments | Operating Segments
Goodwill [Line Items]
Acquisition	19,016
Alfmeier [Member]
Goodwill [Line Items]
Balance, end of period	34,494
Alfmeier [Member] | Operating Segments
Goodwill [Line Items]
Acquisition	34,494
Alfmeier [Member] | Automotive Segments | Operating Segments
Goodwill [Line Items]
Acquisition	$ 34,494

Goodwill and Other Intangible_3

Goodwill and Other Intangibles - Summary of Other Intangible Assets and Accumulated Amortization Balances (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Intangible Assets [Line Items]
Gross Carrying Value	$ 183,846	$ 145,918
Accumulated Amortization	(109,913)	(108,364)
Net Carrying Value	73,933	37,554
Net Carrying Value		37,554
Customer Related
Intangible Assets [Line Items]
Gross Carrying Value	112,286	90,448
Accumulated Amortization	(65,748)	(64,105)
Net Carrying Value	46,538	26,343
Technology
Intangible Assets [Line Items]
Gross Carrying Value	44,745	29,464
Accumulated Amortization	(25,709)	(24,487)
Net Carrying Value	19,036	4,977
Product Development Costs
Intangible Assets [Line Items]
Gross Carrying Value	18,774	20,329
Accumulated Amortization	(18,456)	(19,772)
Net Carrying Value	318	557
Software Development Costs
Intangible Assets [Line Items]
Gross Carrying Value	1,007	1,007
Net Carrying Value	1,007
Tradenames
Intangible Assets [Line Items]
Net Carrying Value	$ 7,034	$ 4,670

Goodwill and Other Intangible_4

Goodwill and Other Intangibles - Additional Information (Detail) - USD ($) $ in Thousands					12 Months Ended
	Aug. 01, 2022	Jul. 13, 2022	Jun. 19, 2020	Feb. 28, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill And Other Intangible Assets [Line Items]
Intangible assets					$ 73,933	$ 37,554
Gain on sale of intangible assets							$ 1,978
Other intangible assets					9,018	8,821	$ 9,226
Technology
Goodwill And Other Intangible Assets [Line Items]
Intangible assets					19,036	4,977
Customer Relationship
Goodwill And Other Intangible Assets [Line Items]
Intangible assets					46,538	26,343
Impairment of intangible asset					$ 5,601
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]					Non-cash impairment charges
Other intangible impairment charges					$ 5,601
Patents and Intellectual Property
Goodwill And Other Intangible Assets [Line Items]
Proceeds from sale of intangible assets			$ 2,055
Patents and Intellectual Property | Other Income
Goodwill And Other Intangible Assets [Line Items]
Gain on sale of intangible assets			$ 1,978
Beckmann & Egle Industrieelektronik GmbH | Technology
Goodwill And Other Intangible Assets [Line Items]
Intangible assets						$ 976
Weighted Average Life (in years)						7 years
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life						7 years
Development Stage Technology Company
Goodwill And Other Intangible Assets [Line Items]
Automotive patents and technology acquired				$ 3,141
Defensive intangible assets, useful life				6 years
Dacheng [Member] | Technology
Goodwill And Other Intangible Assets [Line Items]
Intangible assets					$ 4,749
Weighted Average Life (in years)		12 years			12 years
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life		12 years			12 years
Dacheng [Member] | Customer Relationship
Goodwill And Other Intangible Assets [Line Items]
Intangible assets					$ 12,837
Weighted Average Life (in years)		12 years			12 years
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life		12 years			12 years
Alfmeier [Member] | Technology
Goodwill And Other Intangible Assets [Line Items]
Intangible assets					$ 11,647
Weighted Average Life (in years)	9 years				9 years
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	9 years				9 years
Alfmeier [Member] | Customer Relationship
Goodwill And Other Intangible Assets [Line Items]
Intangible assets					$ 19,812
Weighted Average Life (in years)	14 years				14 years
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	14 years				14 years
Trade Names [Member] | Dacheng [Member]
Goodwill And Other Intangible Assets [Line Items]
Intangible assets					$ 2,473

Goodwill and Other Intangible_5

Goodwill and Other Intangibles - Summary of Estimate of Other Intangible Asset Amortization (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2023	$ 8,294
2024	7,297
2025	7,284
2026	7,284
2027	$ 7,284

Leases - Components of Lease Ex

Leases - Components of Lease Expense and Other Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lease cost:
Operating lease cost	$ 8,040	$ 8,227	$ 6,773
Amortization of ROU assets - finance leases	168
Interest on lease liabilities - finance leases	16
Short-term lease cost	1,773	1,941	1,834
Sublease income	(101)	(163)	(158)
Total lease cost	9,896	10,005	$ 8,449
Operating cash flows for operating leases	10,381	7,685
Operating cash flows for finance leases	16
Financing cash flows for finance leases	164
Right-of-use lease assets obtained in exchange for lease obligations, Operating leases	15,902	$ 2,379
Right-of-use lease assets obtained in exchange for lease obligations, Finance leases	$ 1,180
Weighted-average remaining lease term, Operating leases	5 years 8 months 12 days	6 years 10 months 24 days
Weighted-average remaining lease term, Finance leases	2 years 8 months 12 days
Weighted-average discount rate, Operating leases	4.35%	4.53%
Weighted-average discount rate, Finance leases	3.57%

Leases - Summary of Operating L

Leases - Summary of Operating Leases Under all Non-Cancellable Operating Leases (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 8,074
2024	7,003
2025	4,984
2026	3,122
2027	1,631
2028 or later	6,538
Total future minimum lease payments	31,352
Less imputed interest	(3,671)
Total	$ 27,681

Leases - Summary of Finance Lea

Leases - Summary of Finance Leases Under all Non-Cancellable Finance Leases (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 432
2024	437
2025	148
2026	68
Total future minimum lease payments	$ 1,085

Summary of Company's Debt (Deta

Summary of Company's Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total debt	$ 235,096	$ 38,750
Current maturities	(2,443)	(2,500)
Long-term debt, less current maturities	$ 232,653	$ 36,250
U.S. Revolving Note (U.S. Dollar Denominations)
Debt Instrument [Line Items]
Interest Rate	5.80%	1.35%
Total debt	$ 232,000	$ 35,000
Other Loans
Debt Instrument [Line Items]
Interest Rate		5.21%
Total debt	$ 2,011	$ 3,750
Other Loans | Minimum
Debt Instrument [Line Items]
Interest Rate	3.89%
Other Loans | Maximum
Debt Instrument [Line Items]
Interest Rate	5.21%
Finance Leases
Debt Instrument [Line Items]
Total debt	$ 1,085

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)				12 Months Ended
	Jun. 10, 2027	Jun. 27, 2024	Jun. 10, 2022	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Maximum percentage of stock of non US subsidiaries pledge to secure obligation				66%
Unamortized deferred debt issuance costs written off				$ 144,000
Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Debt issuance cost			$ 1,417,000
Remaining borrowing capacity				$ 264,904,000
Second Amended and Restated Credit Agreement | Federal Funds Rate
Debt Instrument [Line Items]
Interest rate				0.50%
Second Amended and Restated Credit Agreement | SOFR Rate
Debt Instrument [Line Items]
Interest rate				1%
Term SOFR Rate Loans | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate				1.125%
Term SOFR Rate Loans | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate				2.125%
Base Rate Loans | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate				0.125%
Base Rate Loans | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate				1.125%
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity increase subject to specified conditions			200,000,000
Revolving Credit Facility | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity			500,000,000
Line of credit, outstanding amount			35,000,000
Increase in maximum borrowing capacity			25,000,000
Revolving Credit Facility | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.175%
Revolving Credit Facility | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.30%
Revolving Credit Facility | Letters of Credit
Debt Instrument [Line Items]
Line of credit, outstanding amount				$ 0	$ 0
Revolving Credit Facility | Swing Line Loans
Debt Instrument [Line Items]
Maximum borrowing capacity			50,000,000
Standby Letters of Credit | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 15,000,000
Scenario Forecast | Revolving Credit Facility | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Debt maturity date	Jun. 10, 2027
Scenario Forecast | Revolving Credit Facility | Revolving Note (U.S. Dollar)
Debt Instrument [Line Items]
Debt maturity date		Jun. 27, 2024

Principal Maturities of Debt (D

Principal Maturities of Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt maturing in 2023	$ 2,443
Debt maturing in 2024	437
Debt maturing in 2025	148
Debt maturing, 2026	68
Debt maturing, 2027	232,000
Total debt	235,096	$ 38,750
US and Euro Denominated Revolving Note
Debt Instrument [Line Items]
Debt maturing, 2027	232,000
Total debt	232,000
Other Debt
Debt Instrument [Line Items]
Debt maturing in 2023	2,443
Debt maturing in 2024	437
Debt maturing in 2025	148
Debt maturing, 2026	68
Total debt	$ 3,096

Pension and Other Post Retire_3

Pension and Other Post Retirement Benefit Plans - Components of Net Periodic Benefit Cost for Company's Defined Benefit Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
United States
Net periodic benefit cost:
Interest cost	$ 56	$ 42	$ 85
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, General and Administrative Expense	Selling, General and Administrative Expense	Selling, General and Administrative Expense
Amortization of prior service cost and actuarial loss	$ 22	$ 26	$ 7
Net periodic benefit cost	$ 78	$ 68	$ 92
Assumptions:
Discount rate	1.80%	1.20%	2.40%
German Plan
Net periodic benefit cost:
Interest cost	$ 92	$ 91	$ 88
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, General and Administrative Expense	Selling, General and Administrative Expense	Selling, General and Administrative Expense
Expected return on plan assets	$ (109)	$ (120)	$ (121)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax
Amortization of prior service cost and actuarial loss	$ 114	$ 133	$ 124
Net periodic benefit cost	$ 97	$ 104	$ 91
Assumptions:
Discount rate	1.25%	1.08%	1.06%
Long-term return on assets	2.90%	2.90%	3.10%

Pension and Other Post Retire_4

Pension and Other Post Retirement Benefit Plans - Reconciliation of Change in Benefit Obligation, Change in Plan Assets and Balance Sheet Classification (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Balance sheet classification:
Pension benefit obligation	$ (3,638)	$ (6,832)
United States
Change in projected benefit obligation:
Balance at beginning of year	3,446	3,847
Interest cost	56	42	$ 85
Paid pension distributions	(342)	(342)
Actuarial (gain) loss	(349)	(101)
Balance at end of year	2,811	3,446	3,847
Change in plan assets:
Underfunded Status	(2,811)	(3,446)
Balance sheet classification:
Other current liabilities	(342)	(342)
Pension benefit obligation	(2,469)	(3,104)
Accumulated other comprehensive loss (pre-tax):
Actuarial losses	$ 205	$ 575
Discount rate	4.65%	1.80%
German Plan
Change in projected benefit obligation:
Balance at beginning of year	$ 8,102	$ 8,934
Interest cost	92	91	88
Paid pension distributions	(281)	(310)
Actuarial (gain) loss	(2,001)	9
Exchange rate impact	(514)	(622)
Balance at end of year	5,398	8,102	8,934
Change in plan assets:
Balance at beginning of year	4,069	4,276
Actual return on plan assets	89	98
Contributions		310
Paid pension distributions		(310)
Exchange rate impact	(240)	(305)
Balance at end of year	3,918	4,069	$ 4,276
Underfunded Status	(1,480)	(4,033)
Balance sheet classification:
Other current liabilities	(314)	(306)
Pension benefit obligation	(1,166)	(3,727)
Accumulated other comprehensive loss (pre-tax):
Actuarial losses	$ 965	$ 3,288
Discount rate	4.10%	1.25%

Pension and Other Post Retire_5

Pension and Other Post Retirement Benefit Plans - Summary of Pre-tax Amounts in AOCI Expected to Be Recognized in Net Periodic Benefit Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
United States
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses		$ 205	$ 575
German Plan
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses		$ 965	$ 3,288
Scenario Forecast | German Plan
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$ 22

Pension and Other Post Retire_6

Pension and Other Post Retirement Benefit Plans - Summary of Accumulated Benefit Obligations (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
United States
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 2,811	$ 3,446
German Plan
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 5,398	$ 8,102

Pension and Other Post Retire_7

Pension and Other Post Retirement Benefit Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
401(k) Plan
Defined Benefit Plan Disclosure [Line Items]
Cost recognized for contributions to defined contribution plan	$ 1,984,000	$ 1,724,000	$ 1,275,000
United States
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, expected employer contribution in next fiscal year	0
German Plan
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, expected employer contribution in next fiscal year	$ 0

Pension and Other Post Retire_8

Pension and Other Post Retirement Benefit Plans - Schedule of Future Expected Pension Payments (Detail) - Gentherm GmbH $ in Thousands	Dec. 31, 2022 USD ($)
United States
Defined Benefit Plan Disclosure [Line Items]
2023	$ 342
2024	342
2025	342
2026	342
2027	342
2028-2031	1,710
Total projected pension benefit payments	3,420
German Plan
Defined Benefit Plan Disclosure [Line Items]
2023	311
2024	303
2025	294
2026	285
2027	274
2028-2031	2,732
Total projected pension benefit payments	$ 4,199

Commitments and Contingencies -

Commitments and Contingencies - Reconciliation of Changes in Accrued Warranty Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Loss Contingency [Abstract]
Balance at beginning of year	$ 1,916	$ 2,391
Warranty opening balance from acquired entities	907
Warranty claims paid	(1,841)	(2,164)
Warranty expense for products shipped during the current period	1,584	1,813
Adjustments to warranty estimates from prior periods	(274)	(73)
Adjustments due to currency translation	88	(51)
Balance at end of year	$ 2,380	$ 1,916

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Labor Agreements
Loss Contingencies [Line Items]
Percentage of workforce as members of industrial trade unions	31%
Capital Expenditures
Loss Contingencies [Line Items]
Commitments	$ 6,853
Semiconductor Chips
Loss Contingencies [Line Items]
Commitments	$ 40,130
Semiconductor Chips | Maximum
Loss Contingencies [Line Items]
Commitment period	24 years
Semiconductor Chips | Minimum
Loss Contingencies [Line Items]
Commitment period	12 years

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Net income	$ 24,441	$ 93,434	$ 59,690
Basic weighted average shares of Common Stock outstanding	33,126,202	33,085,732	32,666,025
Dilutive effect of stock options, restricted stock awards and restricted stock units	376,952	423,988	362,079
Diluted weighted average shares of Common Stock outstanding	33,503,154	33,509,720	33,028,104
Basic earnings per share	$ 0.74	$ 2.82	$ 1.83
Diluted earnings per share	$ 0.73	$ 2.79	$ 1.81
Anti-dilutive securities share impact			12,000

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2022	Jun. 30, 2022
Derivative [Line Items]
Availability under receivables factoring agreement	$ 5,479,000
Trade receivables	61,482,000
Factoring fees	180,000
Factoring receivables not yet paid	19,108,000
Collective limit under factoring arrangements	24,142,000
Interest Rate Swap
Derivative [Line Items]
Hedge Ineffectiveness Incurred	0	$ 0
Floating to Fixed interest Rate Swap
Derivative [Line Items]
Notional Value					$ 100,000,000
Foreign Currency Derivatives
Derivative [Line Items]
Gain (loss) on derivatives	4,954,000	$ 392,000	$ (1,475,000)
Foreign Currency Derivatives | Foreign Currency (Loss) Gain
Derivative [Line Items]
Gain (loss) on derivatives			$ (118,000)
Foreign Currency Derivatives | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Gain (loss) on derivatives	(3,806,000)
Foreign Currency Derivatives | Derivatives Not Designated as Hedging Instruments | Foreign Currency (Loss) Gain
Derivative [Line Items]
Gain (loss) on derivatives	$ (3,806,000)
Alfmeier | Foreign Currency Derivatives | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Notional Value				$ 128,319,000	$ 128,319,000

Information Related to Recurrin

Information Related to Recurring Fair Value Measurement of Derivative Financial Instruments in the Consolidated Balance Sheet (Detail) - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Foreign Currency Derivatives | Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Notional Amount	$ 40,063	$ 13,974
Net Asset/ (Liabilities)	3,791	294
Foreign Currency Derivatives | Designated as Hedging Instrument | Other Current Assets
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	3,791	294
Commodity Hedges | Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Notional Amount		309
Net Asset/ (Liabilities)		6
Commodity Hedges | Designated as Hedging Instrument | Other Current Assets
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value		$ 6
Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments
Derivatives Fair Value [Line Items]
Notional Amount	100,000
Net Asset/ (Liabilities)	2,772
Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments | Other Current Assets
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 2,772

Information Related to Effect o

Information Related to Effect of Derivative Instruments in the Consolidated Statements of Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 4,954	$ 392	$ (1,475)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives	$ 13	$ 20
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Other comprehensive (loss) income | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 3,496	$ (1,217)	$ 272
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Other comprehensive (loss) income | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives	$ (6)	$ 6
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Derivatives Not Designated as Hedging Instruments | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ (3,806)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Foreign Currency Transaction Gain (Loss), before Tax
Derivatives Not Designated as Hedging Instruments | Interest Rate Contracts
Derivative Instruments Gain Loss [Line Items]
Total interest rate derivatives	$ 2,772
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Net
Cost of sales | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 1,458	$ 1,609	$ (1,629)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold	Cost of Goods and Services Sold	Cost of Goods and Services Sold
Cost of sales | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives	$ 19	$ 14
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold	Cost of Goods and Services Sold
Foreign Currency (Loss) Gain | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives			$ (118)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]			Foreign Currency Transaction Gain (Loss), before Tax
Foreign Currency (Loss) Gain | Derivatives Not Designated as Hedging Instruments | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ (3,806)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Foreign Currency Transaction Gain (Loss), before Tax
Interest Income (Expense), Net | Derivatives Not Designated as Hedging Instruments | Interest Rate Contracts
Derivative Instruments Gain Loss [Line Items]
Total interest rate derivatives	$ 2,772
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Net

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	Jul. 01, 2021	Dec. 31, 2022	Dec. 31, 2021
Beckmann & Egle Industrieelektronik GmbH
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Medical business segment unit amount acquired	$ 2,827,000
Fair Value, Recurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value		$ 0	$ 0
Financial liabilities, fair value		0	0
Fair Value, Nonrecurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value		0	0
Financial liabilities, fair value		$ 0	$ 0

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Common Stock, shares authorized		55,000,000	55,000,000
Preferred stock, shares authorized		4,991,000
Common Stock, shares issued		33,202,082	33,008,185
Common Stock, shares outstanding		33,202,082	33,008,185
Preferred stock, shares issued		0
Preferred stock, shares outstanding		0
Remaining authorized repurchase amount		$ 130,000
2020 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program period	3 years
Stock repurchase program expiration date	Dec. 15, 2023
Maximum
Class Of Stock [Line Items]
Shares issued		59,991,000
Maximum | 2020 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program, authorized to repurchase amount	150,000

Schedule of Reclassification Ad

Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		$ (36,922)		$ (14,982)		$ (42,355)
Other comprehensive income (loss) before reclassifications		(6,478)		(20,350)		25,068
Income tax effect of other comprehensive income (loss) before reclassifications		(2,011)		(437)		593
Amounts reclassified from accumulated other comprehensive loss into net income		(1,340)		(1,464)		2,154
Income taxes reclassified into net income		262		311		(442)
Other comprehensive (loss) income, net of tax		(9,567)		(21,940)		27,373
Ending Balance		(46,489)		(36,922)		(14,982)
Defined Benefit Pension Plans
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		(2,893)		(3,451)		(3,371)
Other comprehensive income (loss) before reclassifications		2,341		512		(328)
Income tax effect of other comprehensive income (loss) before reclassifications		(621)		(71)		117
Amounts reclassified from accumulated other comprehensive loss into net income		137		159		131
Income taxes reclassified into net income		(31)		(42)
Other comprehensive (loss) income, net of tax		1,826		558		(80)
Ending Balance		(1,067)		(2,893)		(3,451)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		(34,188)		(12,637)		(39,879)
Other comprehensive income (loss) before reclassifications		(13,786)		(21,274)		27,147
Income tax effect of other comprehensive income (loss) before reclassifications		(295)		(277)		95
Other comprehensive (loss) income, net of tax		(14,081)		(21,551)		27,242
Ending Balance		(48,269)		(34,188)		(12,637)
Commodity Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		5
Other comprehensive income (loss) before reclassifications		13		20
Income tax effect of other comprehensive income (loss) before reclassifications		(3)		(4)
Amounts reclassified from accumulated other comprehensive loss into net income	[1]	(19)		(14)
Income taxes reclassified into net income		4		3
Other comprehensive (loss) income, net of tax		(5)		5
Ending Balance				5
Foreign Currency Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		154		1,106		895
Other comprehensive income (loss) before reclassifications		4,954		392		(1,751)
Income tax effect of other comprehensive income (loss) before reclassifications		(1,092)		(85)		381
Amounts reclassified from accumulated other comprehensive loss into net income		(1,458)	[1]	(1,609)	[1]	2,023	[2]
Income taxes reclassified into net income		289		350		(442)
Other comprehensive (loss) income, net of tax		2,693		(952)		211
Ending Balance		$ 2,847		$ 154		$ 1,106
[1] The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. The amounts reclassified from Accumulated other comprehensive income (loss) are included in Cost of sales. See Note 13 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income.

Accounting for Stock Based Co_3

Accounting for Stock Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands			12 Months Ended
	May 21, 2020	May 19, 2017	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	May 16, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance based restricted stock units outstanding			13,600	11,376	34,906	34,920
These awards vesting period			1 year 10 months 2 days
Shareholder Return Award Performance Measurement Period			3 years
Deferred tax (expense) benefit			$ (444)	$ 2,725	$ 3,002
Granted, Shares			0	0	0	0	0
Total intrinsic value of options exercised			$ 1,582	$ 8,269	$ 5,317
Total fair value of restricted shares vested			$ 800	$ 1,554	$ 1,499
Performance Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance based restricted stock units outstanding			320,449	319,336	315,834	190,080
These awards vesting period			1 year 11 months 19 days
Awards vesting condition			Company’s achievement of either a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year a target three year cumulative Adjusted EBITDA (“Adjusted EBITDA”), as defined in the award agreement, or the Company’s relative total shareholder return (“TSR”), as defined in the award agreement, during a specific three-year measurement period.
Stock option achieving minimum threshold			50%
Stock option achieving maximum threshold			200%
Total intrinsic value of stock units vested			$ 6,986	$ 4,265	$ 0
ROIC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
These awards vesting period			3 years
RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
These awards vesting period			1 year 9 months 18 days
Total intrinsic value of stock units vested			$ 4,774	$ 3,398	$ 2,214
Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted, Shares			0	0	0	0	0
Total intrinsic value of options exercised			$ 1,348	$ 4,301	$ 4,164
Employee and Consultants | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period			3 years
Employee and Consultants | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period			4 years
Director
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period			1 year
2013 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for grant			2,216,324
Number of shares authorized for grant								3,500,000
Number of increased shares available for grant	2,450,000	2,000,000

Accounting for Stock Based Co_4

Accounting for Stock Based Compensation - Summary of Recognized and Unrecognized Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 6,599	$ 14,530	$ 14,323
Unrecognized Stock-Based Compensation Expense	$ 15,888
Remaining Weighted Average Vesting Period	1 year 10 months 2 days
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 5,551	4,594	3,137
Unrecognized Stock-Based Compensation Expense	$ 8,724
Remaining Weighted Average Vesting Period	1 year 9 months 18 days
PSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 954	5,535	3,361
Unrecognized Stock-Based Compensation Expense	$ 6,745
Remaining Weighted Average Vesting Period	1 year 11 months 19 days
Restricted Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 888	1,198	1,495
Unrecognized Stock-Based Compensation Expense	$ 419
Remaining Weighted Average Vesting Period	5 months 1 day
SARs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ (794)	2,721	5,494
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense		$ 482	$ 836

Accounting for Stock Based Co_5

Accounting for Stock Based Compensation - Summarizes Restricted Stock Unit Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	11,376	34,906	34,920
Granted, Shares	13,600	13,742	32,406
Vested, Shares	(11,376)	(37,272)	(32,420)
Outstanding at end of period, Shares	13,600	11,376	34,906
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 70.33	$ 39.82	$ 38.31
Granted, Weighted-Average Grant Date Fair Value	73.54	70.18	39.96
Vested, Weighted-Average Grant Date Fair Value	70.33	41.70	38.33
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 73.54	$ 70.33	$ 39.82
RSU | Time Vesting Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	193,626	208,905	141,741
Granted, Shares	117,507	93,539	132,864
Vested, Shares	(95,692)	(88,296)	(50,953)
Forfeited, Shares	(13,863)	(20,522)	(14,747)
Outstanding at end of period, Shares	201,578	193,626	208,905
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 56.02	$ 37.26	$ 42.16
Granted, Weighted-Average Grant Date Fair Value	66.86	79.79	34.41
Vested, Weighted-Average Grant Date Fair Value	49.85	38.49	42.13
Forfeited, Weighted-Average Grant Date Fair Value	70.52	48.76	39.16
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 64.27	$ 56.02	$ 37.26

Accounting for Stock Based Co_6

Accounting for Stock Based Compensation - Summarizes Performance Stock Units Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	11,376	34,906	34,920
Granted, Shares	13,600	13,742	32,406
Vested, Shares	(11,376)	(37,272)	(32,420)
Outstanding at end of period, Shares	13,600	11,376	34,906
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 70.33	$ 39.82	$ 38.31
Granted, Weighted-Average Grant Date Fair Value	73.54	70.18	39.96
Vested, Weighted-Average Grant Date Fair Value	70.33	41.70	38.33
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 73.54	$ 70.33	$ 39.82
Performance Based Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	319,336	315,834	190,080
Granted, Shares	106,604	101,136	155,934
Performance Adjustment, Shares	42,746	(2)
Vested, Shares	(133,477)	(61,656)
Forfeited, Shares	(14,760)	(35,976)	(30,180)
Outstanding at end of period, Shares	320,449	319,336	315,834
Performance Based Units | Relative TSR Target Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	131,568	157,918	95,041
Granted, Shares	21,324	20,626	77,967
Performance Adjustment, Shares	45,004	30,828
Vested, Shares	(90,371)	(61,656)
Forfeited, Shares	(4,724)	(16,148)	(15,090)
Outstanding at end of period, Shares	102,801	131,568	157,918
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 62.09	$ 56.06	$ 61.77
Granted, Weighted-Average Grant Date Fair Value	103.31	118.08	49.25
Performance Adjustment, Weighted-Average Grant Date Fair Value	57.46	69.18
Vested, Weighted-Average Grant Date Fair Value	57.46	69.18
Forfeited, Weighted-Average Grant Date Fair Value	68.67	61.10	56.84
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 65.20	$ 62.09	$ 56.06
Performance Based Units | ROIC Target Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	150,292	157,916	95,039
Granted, Shares	42,640	40,580	77,967
Performance Adjustment, Shares	(2,258)	(30,830)
Vested, Shares	(43,106)
Forfeited, Shares	(6,493)	(17,374)	(15,090)
Outstanding at end of period, Shares	141,075	150,292	157,916
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 47.52	$ 38.58	$ 42.78
Granted, Weighted-Average Grant Date Fair Value	68.63	78.98	33.72
Performance Adjustment, Weighted-Average Grant Date Fair Value	41.61	44.92
Vested, Weighted-Average Grant Date Fair Value	41.61
Forfeited, Weighted-Average Grant Date Fair Value	56.87	44.32	39.96
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 55.18	$ 47.52	$ 38.58
Performance Based Units | Adjusted EBITDA Target Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	37,476
Granted, Shares	42,640	39,930
Forfeited, Shares	(3,543)	(2,454)
Outstanding at end of period, Shares	76,573	37,476
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 79.49
Granted, Weighted-Average Grant Date Fair Value	68.63	$ 79.49
Forfeited, Weighted-Average Grant Date Fair Value	75.10	79.49
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 73.66	$ 79.49

Accounting for Stock Based Co_7

Accounting for Stock Based Compensation - Summarizes Restricted Stock Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Outstanding at beginning of period, Shares	11,376	34,906	34,920
Granted, Shares	13,600	13,742	32,406
Vested, Shares	(11,376)	(37,272)	(32,420)
Outstanding at end of period, Shares	13,600	11,376	34,906
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 70.33	$ 39.82	$ 38.31
Granted, Weighted-Average Grant Date Fair Value	73.54	70.18	39.96
Vested, Weighted-Average Grant Date Fair Value	70.33	41.70	38.33
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 73.54	$ 70.33	$ 39.82

Accounting for Stock Based Co_8

Accounting for Stock Based Compensation - Summarizes Stock Appreciation Rights (SARs) Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options Outstanding, beginning balance, Shares	206,750	428,000	869,000
Granted, Shares	0	0	0	0	0
Exercised, Shares	(44,116)	(215,250)	(434,250)
Forfeited, Shares		(6,000)	(6,750)
Stock Options Outstanding, ending balance, Shares	162,634	206,750	428,000	869,000
Exercisable, Ending Balance	162,634
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 36.72	$ 37.61	$ 37.87
Exercised, Weighted-Average Exercise Price	37.87	38.46	38.12
Forfeited, Weighted-Average Exercise Price		38.05	38.05
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	36.41	$ 36.72	$ 37.61	$ 37.87
Exercisable, Weighted Average Exercise Price	$ 36.41
Stock Options Outstanding, Weighted-Average Remaining Contractual Term	2 years 8 months 4 days	2 years 7 months 6 days	3 years 2 months 12 days	3 years 6 months 3 days
Exercisable, Weighted-Average Remaining Contractual Term	2 years 8 months 4 days
Outstanding, Aggregate Intrinsic Value	$ 8,212	$ 10,375	$ 11,815	$ 5,172
Exercisable, Aggregate Intrinsic Value	$ 8,212
Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options Outstanding, beginning balance, Shares	55,600	171,600	554,250
Granted, Shares	0	0	0	0	0
Exercised, Shares	(40,850)	(116,000)	(342,150)
Forfeited, Shares			(40,500)
Stock Options Outstanding, ending balance, Shares	14,750	55,600	171,600	554,250
Exercisable, Ending Balance	14,750
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 41.15	$ 40.60	$ 39.41
Exercised, Weighted-Average Exercise Price	42.27	40.34	38.22
Forfeited, Weighted-Average Exercise Price			44.39
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	38.05	$ 41.15	$ 40.60	$ 39.41
Exercisable, Weighted Average Exercise Price	$ 38.05
Stock Options Outstanding, Weighted-Average Remaining Contractual Term	1 year 1 month 24 days	1 year 3 months 10 days	2 years 5 months 8 days	2 years 10 months 2 days
Exercisable, Weighted-Average Remaining Contractual Term	1 year 1 month 24 days
Outstanding, Aggregate Intrinsic Value	$ 402	$ 2,544	$ 4,224	$ 2,981
Exercisable, Aggregate Intrinsic Value	$ 402

Accounting for Stock Based Co_9

Accounting for Stock Based Compensation - Summarizes Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-Based Payment Arrangement [Abstract]
Stock Options Outstanding, beginning balance, Shares	206,750	428,000	869,000
Granted, Shares	0	0	0	0	0
Exercised, Shares	(44,116)	(215,250)	(434,250)
Forfeited, Shares		(6,000)	(6,750)
Stock Options Outstanding, ending balance, Shares	162,634	206,750	428,000	869,000
Stock Options Exercisable, Shares	162,634
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 36.72	$ 37.61	$ 37.87
Exercised, Weighted-Average Exercise Price	37.87	38.46	38.12
Forfeited, Weighted-Average Exercise Price		38.05	38.05
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	36.41	$ 36.72	$ 37.61	$ 37.87
Exercisable, Weighted-Average Exercise Price	$ 36.41
Stock Options Outstanding, Weighted-Average Remaining Contractual Term	2 years 8 months 4 days	2 years 7 months 6 days	3 years 2 months 12 days	3 years 6 months 3 days
Exercisable, Weighted-Average Remaining Contractual Term	2 years 8 months 4 days
Stock Options Outstanding, Aggregate Intrinsic Value	$ 8,212	$ 10,375	$ 11,815	$ 5,172
Exercisable, Aggregate Intrinsic Value	$ 8,212

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
Undistributed earnings offsetting with dividend received deduction percent	100%
Valuation allowance	$ 36,671	$ 16,090
Total unrecognized tax benefits	$ 6,185	$ 5,665	$ 4,967	$ 3,795
U.S. State | Earliest Tax Year
Income Taxes [Line Items]
Operating loss carryforward, year of expiration	2023
U.S. State | Latest Tax Year
Income Taxes [Line Items]
Operating loss carryforward, year of expiration	2042
Non-U.S. Subsidiaries
Income Taxes [Line Items]
Operating loss carryforward, amount	$ 320,417
Net operating loss carryforward, year of expiration	no expiration date
Valuation allowance	$ 133,877
Foreign Jurisdictions
Income Taxes [Line Items]
Income tax holiday, description	The Company currently benefits from tax holidays in various non-U.S. jurisdictions with expiration dates from 2024 – 2025.

Income Taxes - Earnings Before

Income Taxes - Earnings Before Income Taxes and Tax Provisions - (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings before income tax:
Domestic	$ (34,211)	$ (4,547)	$ (11,374)
Foreign	72,593	118,399	92,930
Earnings before income tax	$ 38,382	$ 113,852	$ 81,556

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current income tax expense:
Federal	$ 3,006	$ 1,944	$ 784
State and local	650	234	83
Foreign	17,607	18,390	20,150
Total current income tax expense	21,263	20,568	21,017
Deferred income tax (benefit) expense:
Federal	(5,971)	(4,400)	(2,302)
State and local	(213)	(91)	32
Foreign	(1,138)	4,341	3,119
Total deferred (benefit) income tax expense	(7,322)	(150)	849
Total income tax expense	$ 13,941	$ 20,418	$ 21,866

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating losses	$ 43,296	$ 25,610
Intangible assets	4,417	21,179
Research and development credits	7,835	9,736
Property and equipment	6,983	7,071
Valuation reserves and accrued liabilities	8,388	7,333
Capitalized Research and Development Costs	19,087	9,018
Stock compensation	3,051	3,832
Defined benefit obligation	1,265	1,466
Inventory	6,762	1,914
Other credits	10,296	10,158
Other	790	146
Total deferred tax asset	112,170	97,463
Valuation allowance	(36,671)	(16,090)
Deferred tax liabilities:
Unrealized foreign currency exchange gains	(2,413)	(2,488)
Undistributed profits of subsidiary	(5,981)	(6,676)
Property and equipment	(15,423)	(2,420)
Other	(3,056)	(1,428)
Total deferred tax liability	(26,873)	(13,012)
Net deferred tax asset	$ 48,626	$ 68,361

Income Taxes - Reconciliations

Income Taxes - Reconciliations Between Statutory Federal Income Tax Rate and Effective Rate (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory Federal income tax rate	21%	21%	21%
Increase (decrease) resulting from:
Change in valuation allowance	6.40%	(1.20%)	(0.40%)
Effect of different tax rates of foreign jurisdictions	(4.90%)	(5.20%)	(4.70%)
Tax credits & deductions related to R&D	(10.10%)	(2.30%)	(3.80%)
Non-deductible expenses	14.90%	1.70%	2.10%
Non-deductible expenses related to acquisitions	7%	0%	0%
Other foreign, state and local taxes	0.70%	1.60%	1.40%
Tax impact of foreign income	4.20%	3.60%	4.90%
Stock Option Compensation	(3.80%)	(2.00%)	(0.40%)
Other	0.90%	0.70%	6.70%
Effective rate	36.30%	17.90%	26.80%

Income Taxes - Net Operating Lo

Income Taxes - Net Operating Loss Carryforwards (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
U.S. state income tax
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, amount	$ 54,912
U.S. state income tax | Minimum
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, year of expiration	2023
U.S. state income tax | Maximum
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, year of expiration	2042
Foreign, Indefinite
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, amount	$ 320,417
Operating loss carryforward, year of expiration	Indefinite

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Balance at beginning of year	$ 5,665	$ 4,967	$ 3,795
Additions based on tax position related to current year	972	1,105	1,489
Additions based on tax position related to prior year	433	160	179
Reductions from settlements and statute of limitation expiration	(610)	(312)	(650)
Effect of foreign currency translation	(275)	(255)	154
Balance at end of year	$ 6,185	$ 5,665	$ 4,967

Segment Reporting - Segment Inf

Segment Reporting - Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Product revenues	$ 1,204,656	$ 1,046,150	$ 913,098
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 44,394	$ 38,780	$ 41,114
Operating income (loss)	48,307	115,006	89,217
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues	$ 1,161,616	$ 1,004,633	$ 869,998
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 39,815	$ 35,389	$ 37,662
Operating income (loss)	118,433	162,994	138,410
Medical Segments
Segment Reporting Information [Line Items]
Product revenues	$ 43,040	$ 41,517	$ 43,100
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 3,344	$ 2,460	$ 2,366
Operating income (loss)	$ (4,029)	$ (1,829)	$ 971
Corporate Segments
Segment Reporting Information [Line Items]
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 1,235	$ 931	$ 1,086
Operating income (loss)	$ (66,097)	$ (46,159)	$ (50,164)

Segment Reporting - Segment I_2

Segment Reporting - Segment Information About Reported Segment Product Revenues by Product Category (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Product revenues		$ 1,204,656	$ 1,046,150	$ 913,098
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues		1,161,616	1,004,633	869,998
Automotive Segments | Climate Control Seat
Segment Reporting Information [Line Items]
Product revenues		426,046	393,816	342,550
Automotive Segments | Seat Heaters
Segment Reporting Information [Line Items]
Product revenues		283,970	270,054	249,665
Automotive Segments | Steering Wheel Heaters
Segment Reporting Information [Line Items]
Product revenues		120,949	102,496	76,272
Automotive Segments | Automotive Cables
Segment Reporting Information [Line Items]
Product revenues		76,962	84,114	73,997
Automotive Segments | Battery Performance Solutions
Segment Reporting Information [Line Items]
Product revenues		71,907	69,594	50,901
Automotive Segments | Electronics
Segment Reporting Information [Line Items]
Product revenues		44,106	51,648	53,238
Automotive Segments | Lumbar and Massage Comfort Solutions
Segment Reporting Information [Line Items]
Product revenues	[1]	56,980
Automotive Segments | Valve System Technologies
Segment Reporting Information [Line Items]
Product revenues	[1]	41,980
Automotive Segments | Other Automotive
Segment Reporting Information [Line Items]
Product revenues		38,716	32,911	23,375
Industrial Segments | Medical
Segment Reporting Information [Line Items]
Product revenues	[1]	$ 43,040	$ 41,517	$ 43,100
[1] Includes product revenues from acquisitions since their respective acquisition dates (see Note 4).

Segment Reporting (Detail)

Segment Reporting (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Product revenues	$ 1,204,656	$ 1,046,150	$ 913,098
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
United States
Segment Reporting Information [Line Items]
Product revenues	$ 472,468	$ 404,466	$ 377,577
China
Segment Reporting Information [Line Items]
Product revenues	183,419	142,816	101,039
South Korea
Segment Reporting Information [Line Items]
Product revenues	94,937	93,516	88,745
Germany
Segment Reporting Information [Line Items]
Product revenues	75,367	66,929	58,536
Japan
Segment Reporting Information [Line Items]
Product revenues	57,718	63,527	57,785
Czech Republic
Segment Reporting Information [Line Items]
Product revenues	49,293	43,931	37,542
Romania
Segment Reporting Information [Line Items]
Product revenues	47,532	51,367	33,147
Slovakia
Segment Reporting Information [Line Items]
Product revenues	34,686	30,004	21,568
Finland
Segment Reporting Information [Line Items]
Product revenues	33,627	29,325	15,958
Mexico
Segment Reporting Information [Line Items]
Product revenues	23,233	18,194	13,429
Other
Segment Reporting Information [Line Items]
Product revenues	132,376	102,075	107,772
Non U.S.
Segment Reporting Information [Line Items]
Product revenues	$ 732,188	$ 641,684	$ 535,521

Segment Reporting - Percentage

Segment Reporting - Percentage of Total Product Revenues Generated from Customers (Detail) - Sales Revenue, Net - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lear
Segment Reporting Information [Line Items]
Total product revenues in percentage	16%	15%	15%
Adient
Segment Reporting Information [Line Items]
Total product revenues in percentage	15%	15%	14%

Segment Reporting - Segment Rep

Segment Reporting - Segment Reporting About Property and Equipment, Net by Geographic Areas (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Property and equipment, net	$ 244,480	$ 155,270
Germany
Segment Reporting Information [Line Items]
Property and equipment, net	47,342	16,174
China
Segment Reporting Information [Line Items]
Property and equipment, net	43,162	25,411
United States
Segment Reporting Information [Line Items]
Property and equipment, net	41,034	19,222
Mexico
Segment Reporting Information [Line Items]
Property and equipment, net	31,597	20,296
North Macedonia
Segment Reporting Information [Line Items]
Property and equipment, net	27,808	32,682
Vietnam
Segment Reporting Information [Line Items]
Property and equipment, net	19,808	19,876
Czech Republic
Segment Reporting Information [Line Items]
Property and equipment, net	11,381
Hungary
Segment Reporting Information [Line Items]
Property and equipment, net	11,736	8,995
UKRAINE
Segment Reporting Information [Line Items]
Property and equipment, net	5,077	9,539
Other
Segment Reporting Information [Line Items]
Property and equipment, net	$ 5,535	$ 3,075

Valuation and Qualifying Acco_2

Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Allowance for Doubtful Accounts
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 1,399	$ 1,161	$ 1,193
Charged to Costs and Expenses	1,088	1,066	1,298
Other Activity		(12)	33
Deductions from Reserves	(1,267)	(816)	(1,363)
Balance at End of Period	1,220	1,399	1,161
Allowance for Deferred Income Tax Assets
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	16,090	17,197	17,316
Charged to Costs and Expenses	2,482	357
Other Activity	18,099	(102)	139
Deductions from Reserves		(1,362)	(258)
Balance at End of Period	36,671	16,090	17,197
Reserve for Inventory
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	6,014	7,141	6,073
Charged to Costs and Expenses	15,923	2,499	1,768
Other Activity	(133)	(134)	214
Deductions from Reserves	(2,558)	(3,492)	(914)
Balance at End of Period	$ 19,246	$ 6,014	$ 7,141